yevkhtm form ktable content united states securities exchange commission washington annual report pursuant section security exchange act fiscal year end december transition report pursuant section security exchange act transition period commission file number scheringplough corporation exact registrant specify charter new jersey state jurisdiction irs employer incorporation organization identification gallop hill road kenilworth address principal executive office zip code registrant telephone number include area code security register pursuant section act title class exchange register common share par value new york stock exchange mandatory convertible preferred stock new york stock exchange prefer share purchase right new york stock exchange time filing right trade separately common share security register pursuant section act indicate check mark registrant wellknown seasoned issuer define rule security act yes indicate check mark registrant require file report pursuant section section act yes indicate check mark registrant file report require file section security exchange act precede month short period registrant require file report subject filing requirement past day yes indicate check mark disclosure delinquent filer pursuant item regulation chapter contain contain good registrant knowledge definitive proxy information statement incorporate reference iii amendment indicate check mark registrant large accelerated filer accelerate filer nonaccelerate filer small reporting company definition large accelerate filer accelerate fil small reporting company rule exchange act check nonaccelerate filer large accelerated filer accelerate filer check small reporting company small reporting company indicate check mark registrant shell company define rule act yes state aggregate market value vote nonvoting common equity hold nonaffiliate compute reference price common equity sell average bid ask price common equity june business day registrant recently complete second fiscal quarter common share outstanding january document incorporate referenc incorporate scheringplough corporation proxy statement iii annual meeting shareholder table content item business item risk factor item unresolved staff comment item property item legal proceeding item submission matter vote security holder executive officer registrant item market registrant common equity relate stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure management report internal control financial reporting iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item principal accountant fee service item exhibit financial statement schedule signature exd stock incentive plan exeviii employment agreement brent saunder exj severance benefit plan computation ratio earning fix charge subsidiary consent independent register public accounting firm independent auditor consent power attorney certification certification certification certification table content item business overview business scheringplough refer scheringplough corporation subsidiary indicate context schering corporation predecessor company incorporate new york new jersey trademark indicate capital letter property license promote distribute scheringplough corporation subsidiary relate company scheringplough innovationdriven sciencecentere global health care company biopharmaceutical research collaboration partner scheringplough create therapy help save improve life world scheringplough apply researchanddevelopment platform human prescription animal health consumer product scheringplough vision earn trust day doctor patient customer shareholder employee stakeholder scheringplough base kenilworth web site wwwscheringploughcom april board director recruit fred hassan join scheringplough new chairman board chief executive officer support board soon arrive hassan instal new senior executive management team initiate strategic plan goal stabilize repair turn scheringplough order build longterm shareholder value strategic plan action agenda eightyear fivephase plan year hassan new management team arrive scheringplough substantial progress fourth phase action agenda build base scheringplough grow broaden base market product expand late stage research development project pipeline close transformative acquisition organon biosciences obs akzo nobel acquire obs scheringplough gain organon human prescription business intervet animal health business additional strength key scheringplough current environment pharmaceutical industry continue subject evermore critical scrutiny challenge arise present scientific datum objective manner scheringplough believe new scientific datum well present discuss appropriate scientific medical forum explain detail later early scheringplough encounter challenge result merckscheringplough pharmaceutical merckscheringplough cholesterol joint venture clinical trial call enhance joint venture product zetia vytorin subject media scrutiny prior presentation trial result appropriate medical forum result schedule present american college cardiology meeting march trial fail statistically significant difference treatment group primary endpoint mean change intimamedia thickness measure site carotid artery right leave common carotid internal carotid carotid bulb patient heterozygous familial hypercholesterolemia trial demonstrate vytorin effectiveness compare simvastatin lower ldl cholesterol know bad cholesterol medical expert health advisory group long recognize high ldl cholesterol significant cardiovascular risk factor recommend increasingly aggressive treatment high cholesterol certain patient lower ldl cholesterol healthy diet lifestyle change remain cornerstone lipid treatment patient risk heart disease clinical study demonstrate vytorin lower patient ldl cholesterol rosuvastatin atorvastatin simvastatin dose study able patient ldl cholesterol goal define atp iii early tell impact joint venture enhance trial result joint venture cholesterol business scheringploughs diversify group product geographic area highly experienced executive team give scheringplough additional strength helpful weather situation table content segment information scheringplough reportable segment human prescription pharmaceutical animal health consumer health care segment sale lossprofit datum follow consistent scheringplough current management reporting structure human prescription pharmaceutical human prescription pharmaceutical segment discover develop manufacture market human pharmaceutical product human prescription pharmaceutical segment scheringplough broad range research project market product therapeutic area cardiovascular central nervous system immunology infectious disease oncology respiratory womens health human prescription pharmaceutical segment include nobilon human vaccine development unit diosynth thirdparty manufacturing unit market product include follow cardiovascular disease vytorin cholesterollowere tablet combine dual action zetia merck inc statin zocor simvastatin zetia novel cholesterolabsorption inhibitor discover scheringplough scientist use monotherapy combination statin fenofibrate low cholesterol integrilin injection platelet receptor iibiiia inhibitor treatment patient acute coronary syndrome undergo percutaneous coronary intervention united states prevention early myocardial infarction patient acute coronary syndrome country orgaran nonheparin antithrombotic central nervous system remeron antidepressant esmeronzemuron muscle relaxant surgical procedure subutex sublingual tablet formulation buprenorphine suboxone sublingual tablet combination buprenorphine naloxone market scheringplough certain country outside united states treatment opiate addiction norcuron muscle relaxant immunology infectious disease remicade antitnf antibody market scheringplough outside united states japan certain asian market treatment inflammatory disease rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylose spondylitis plaque psoriasis ulcerative colitis pegintron powder injection pegylate interferon product chronic hepatitis avelox market broadspectrum fluoroquinolone antibiotic certain respiratory skin infection noxafil oral suspension prophylaxis prevention invasive fungal infection highrisk patient treatment oropharyngeal candidiasis approve treatment invasive fungal infection market outside oncology temodartemodal capsule certain type brain tumor include newly diagnose glioblastoma multiforme caelyx longcirculating pegylate liposomal formulation cancer drug doxorubicin market scheringplough outside united states treatment certain ovarian cancer kaposis sarcoma metastatic breast cancer intron injection market chronic hepatitis numerous anticancer indication worldwide include adjuvant therapy malignant melanoma respiratory nasonex oncedaily nasalinhale steroid nasal allergy symptom include congestion treatment nasal polyp patient year age old clarinexaerius nonsedate antihistamine treatment allergic rhinitis foradil aerolizer longacting betaagonist market scheringplough united states maintenance treatment asthma chronic obstructive pulmonary disease acute prevention exerciseinduce bronchospasm asmanex twisthaler oral drypowder corticosteroid inhaler firstline maintenance treatment asthma proventil hfa albuterol inhalation solution relief bronchospasm patient year old women health follistimpuregon fertility treatment nuvare vaginal contraceptive ring livial menopausal therapy marvelondesogen lowdose combine oral contraceptive mercilon lowdose combine oral contraceptive implanon singlerod subdermal contraceptive implant table content animal health animal health segment discover develop manufacture market animal health product include vaccine principal market product segment include livestock product nuflor bovine swine antibiotic bovilisvista vaccine line infectious disease cattle banamine bovine swine antiinflammatory trimerit datum management tool cattle regumatematrix fertility management swine horse resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease mpac swine pneumonia vaccine porcilis vaccine line infectious disease swine poultry product nobilisinnovax vaccine line poultry paracox coccivac coccidiosis vaccine poultry companion animal product galaxyquantumprocyoneclipseintratrac vaccine line dog cat nobivaccontinuum vaccine line flexible dog cat vaccination otomaxmometamax canine otic ointment acute chronic otitis caninsulinvetsulin diabete mellitus treatment dog cat panacursafeguard broadspectrum anthelmintic dewormer use animal scaliborexspot dog collarspot protect bite flea tick mosquitoe sandfly homeagain proactive pet recovery network zubrin antiinflammatoryanalgesic dog aquaculture product norvaxminova vaccine bacterial viral disease fish slice parasiticide sea lice salmon aquaflor antibiotic farmraised fish consumer health care consumer health care segment develop manufacture market otc foot care sun care product principal product segment include overthecounter otc product claritin nonsedate antihistamine miralax treatment occasional constipation coricidin hbp decongestantfree coldflu medicine people high blood pressure drixoral cold allergy allergy sinus flu nasal decongestant tablet afrin nasal decongestant spray correctol laxative tablet foot care scholl foot care product lotrimin topical antifungal product tinactin topical antifungal product foot sneaker odorwetness product sun care coppertone sun care lotion spray dry oil lipprotection product sunless tanning product solarcaine sunburn relief product net sale segment yea end decem dollar million human prescription pharmaceutical animal health consumer health care consolidate net sale table content lossprofit segment year nde ecem dollar million human prescription pharmaceutical animal health consumer health care corporate include net interest income million million million respectively consolidate lossprofit tax cumulative effect change accounting principle human prescription pharmaceutical segment loss include billion purchase accounting item include acquire inprocess research development billion animal health segment loss include million purchase accounting item include acquire inprocess research development million scheringplough net sale include sale vytorin zetia manage joint venture merck scheringplough account joint venture equity method accounting note equity income item financial statement supplementary datum additional information equity income merckscheringplough joint venture include human prescription pharmaceutical segment corporate include interest income expense foreign exchange gain loss currency option gain headquarters expense special acquisition relate charge miscellaneous item accounting policy segment report describe note summary significant accounting policy item financial statement supplementary datum corporate include special acquisition relate charge million comprise million integration relate cost obs acquisition million severance charge integration activity estimate charge relate reportable segment follow human prescription pharmaceutical million animal health million corporate million corporate include special charge million primarily relate change scheringploughs manufacturing operation puerto rico announce june relate human prescription pharmaceutical segment include cost sale charge approximately million manufacturing streamlining action primarily relate human prescription pharmaceutical segment corporate include special charge million include million employee termination cost million asset impairment charge increase litigation reserve million result total reserve approximately million represent scheringplough current estimate resolve massachusetts investigation investigation state litigation disclose awp litigation investigation note legal environmental regulatory matter item financial statement supplementary datum estimate charge relate reportable segment follow human prescription pharmaceutical million consumer health care million animal health million corporate million note special acquisition relate charge manufacture streamline item financial statement supplementary datum additional information table content information merckscheringplough joint venture scheringplough merck inc merck enter separate set agreement jointly develop manage certain product include cholesterollowere drug allergyasthma drug december cholesterol agreement expand include country world japan general company agree collaborative activity agreement operate virtual joint venture maximum degree possible rely respective infrastructure company agreement generally provide equal sharing development cost copromotion approve product company cholesterol agreement provide scheringplough merck jointly develop commercialize ezetimibe cholesterol management field oncedaily monotherapy market zetia asia ezetrol europe coadministration approve statin drug iii fixedcombination tablet ezetimibe simvastatin zocor merck cholesterolmodifye medicine combination medication ezetimibesimvastatin market vytorin inegy international country zetiaezetrol ezetimibe vytorininegy combination ezetimibesimvastatin approve use launch international market scheringplough utilize equity method accounting recording share activity merckscheringplough joint venture note equity income item financial statement supplemental datum additional information profit cost share accounting provide agreement allergyasthma agreement provide joint development marketing company oncedaily fixedcombination tablet contain claritin singulair singulair merck oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis new drug application filing combination tablet accept food drug administration fda standard review scheringplough announce agree merck commence development singletablet combination ezetimibe atorvastatin treatment elevate cholesterol level information centocor license remicade license manufactured centocor inc johnson johnson company scheringplough exercise option contract centocor license right develop commercialize golimumab fully human monoclonal antibody currently phase iii trial scheringplough exclusive marketing right product outside japan certain asian market december scheringplough centocor revise distribution agreement development commercialization distribution remicade golimumab extend scheringploughs right exclusively market remicade match duration scheringplough exclusive marketing right golimumab effective regulatory approval golimumab scheringploughs marketing right product extend year commercial sale golimumab centocor receive progressively increase share profit scheringplough distribution product scheringplough marketing territory share profit remain fixed remainder term change duration remicade marketing right profit share arrangement product condition approval golimumab grant prior september scheringplough independently develop market golimumab crohns disease indication territory option centocor participate table content global operation majority scheringplough operation outside acquisition obs late scheringploughs global operation human prescription pharmaceutical animal health increase nonus activity carry primarily whollyowne subsidiary market potential adequate circumstance permit addition scheringplough represent market licensee distribution arrangement currently scheringplough business operation country additional information global operation item management discussion analysis financial condition result operation segment information describe net sale geographic area dollar millions united states europe canada latin america pacific area asia consolidate net sale scheringplough subsidiary country outside net sale present geographic area scheringplough customer locate follow country account percent consolidated net sale past year consolidated net consolidated net consolidated net sale net sale sale net sale sale net sale dollar million total international net sale france japan canada italy net sale customer sale single customer account percent scheringploughs consolidate net sale past year follow consolidated net consolidated net consolidated net sale net sale sale net sale sale net sale dollar million mckesson corporation cardinal health table content supplemental sale information sale product comprise percent scheringplough international sale year end december follow mount rcentage dollar million nasonex otc claritin international remicade scheringplough net sale include sale vytorin zetia manage joint venture merck scheringplough account joint venture equity method accounting longlive asset geographic location dollar millions united states netherlands ireland singapore total longlived asset show geographic location primarily intangible property significant increase longlive asset december obs acquisition scheringplough disaggregate asset segment basis internal management report information present research development scheringplough research activity primarily aim discover develop new prescription product enhancement exist human prescription product medical commercial significance scheringplough research development platform support animal health consumer health care product research development project application product segment companysponsore research development expenditure billion billion billion respectively percentage consolidated net sale research development expenditure represent approximately percent percent percent respectively scheringplough research activity concentrate therapeutic area focus cardiovascular central nervous system immunology infectious disease oncology respiratory women health scheringplough substantial effort direct biotechnology vaccine development immunology research activity include expenditure internal research effort research collaboration partner pharmaceutical compound vary stage development predict compound available commercial sale scheringplough product pipeline list significant product development available scheringplough website wwwscheringploughcom nature development approval process fact human table content health involve science human health constantly evolve status compound development subject change scheringplough assume duty update information scheringplough research development project grant fasttrack designation fda include novel thrombin receptor antagonist acute coronary syndrome secondary prevention subsequent cardiovascular event boceprevir protease inhibitor compound hepatitis vicriviroc ccr receptor antagonist treatment hiv adenosine receptor antagonist treatment parkinson disease product phase iii clinical testing phase thrombin receptor antagonist vicriviroc significant expenditure require progress development large number patient necessary phase iii trial research development expense expect continue increase year primary reason schering plough pipeline large new management team focus make research development productive additional pipeline project add obs acquisition reason include need large clinical trial frequent clinical trial long clinical trial current global regulatory environment research development activity typically continue product market reason learn new indication product reason respond safety effectiveness benefit risk know people use product long period time patent trademark intellectual property right overview intellectual property protection critical scheringplough ability successfully commercialize product innovation schere plough own apply license right large number patent country relate compound formulation use manufacturing process assurance patent scheringplough seeking grant patent scheringplough grant find valid challenge patent relate particular formulation use process preclude manufacturer employ alternative process market alternative formulation use successfully compete scheringplough patent product outside standard intellectual property protection pharmaceutical vary widely country reasonably strong patent law country currently provide little effective protection invention intellectual property right traderelate aspect intellectual property agreement trip administer world trade organization wto country agree provide nondiscriminatory protection pharmaceutical invention assure adequate effective right available patent owner possible change agreement future diminish delay implementation develop country soon assess scheringplough impact commercially change product patent expire patent holder lose effective market exclusivity product result rapid sharp material decline sale patent product particularly case innovator company obtain additional commercial benefit manufacture trade secret laterexpire patent process use formulation trademark use exclusivity available pharmaceutical regulatory law scheringplough intellectual property portfolio patent protection certain scheringplough compound formulation process use important scheringploughs business financial result scheringplough product addition patent compound scheringplough hold patent manufacturing process formulation use extend exclusivity expiration compound patent table content scheringplough subsidiary license right number patent patent application abroad patent patent application relate scheringplough significant product include limitation vytorin zetia remicade nasonex follistimpuregon nuvare temodar pegintron clarinex material importance scheringplough worldwide scheringplough sell major product trademark material aggregate business financial result trademark protection vary world protection continue country long mark country long register registration normally fix renewable term patent challenge hatchwaxman act drug price competition patent term restoration act commonly know hatchwaxman complex set change patent new drug approval law hatchwaxman drug approve provide food drug administration fda complete safety efficacy study know complete new drug application nda hatch waxman authorize fda approve generic version innovative medicine information file abbreviate new drug application anda anda generic manufacturer demonstrate bioequivalence generic version ndaapprove drug safety efficacy hatchwaxman provide limited patent term restoration partially patent term lose time ndaapprove drug regulatory review ndaapprove drug receive limited period datum exclusivity prevent approval anda application specific time period approval ndaapprove drug absent successful patent challenge fda approve anda innovators patent expire generic manufacturer file anda seek approval expiration applicable datum exclusivity allege patent list innovators nda invalid infringe allegation commonly know paragraph certification innovator file suit generic manufacturer protect patent ndaliste patent successfully challenge fil paragraph certification entitle day period market exclusivity generic manufacturer recent year generic manufacturer paragraph certification extensively challenge patent wide array innovative pharmaceutical anticipate trend continue scheringplough include list hatchwaxman act challenge patent legal proceeding section marketing activity competition scheringplough train professional sale representative introduce make know prescription drug physician pharmacist hospitals manage care organization buy group scheringplough sell prescription drug hospital certain manage care organization wholesale distributor retail pharmacist scheringplough introduce make know prescription product journal advertise direct mail advertising distribution sample physicians television radio internet print advertising medium scheringplough train professional sale representative promote animal health product veterinarian distributor animal producer scheringplough sell overthecounter otc foot care sun care product wholesale retail drug food chain mass merchandiser outlet scheringplough promote directly consumer television radio internet print advertising media pharmaceutical industry highly competitive include large company significantly large scheringplough substantial resource research product development advertising promotion field sell support table content numerous domestic international competitor industry principal competitive technique scheringplough product include research development new improve product vary dosage form strength switch prescription product nonprescription status scheringploughs product subject increasingly competitive pricing manage care group institution federal state government entity agency buy group seek price discount rebate governmental thirdparty payer practice pharmacist pressure dispense generic product significantly reduce sale certain product compete product therapeutic category long protect patent exclusivity available pharmaceutical regulatory law scheringplough operate primarily prescription pharmaceutical marketplace appropriate scheringplough seek regulatory approval switch prescription product overthecounter status mean extend product life cycle way otc marketplace mean maximize return investment discovery development government regulation scheringplough major business segment subject significant regulation multiple jurisdiction section describe general regulatory framework additional information cost regulatory compliance specific impact scheringplough business financial condition describe head regulatory competitive environment scheringplough operate management discussion analysis later additional information regulatory matter find note legal environmental regulatory matter item financial statement supplementary datum prescription drug segment regulation apply phase business include regulatory requirement conduct standard clinical trial example require use good clinical practice gcp apply research development stage regulatory requirement conduct standard postapproval clinical trial require regulatory approval begin market new drug market exist drug product new indication regulation prescribe manner drug manufacture package label advertise market distribute regulation impact pricing drug regulatory requirement assess report adverse impact effect drug clinical trial market drug call pharmacovigilance ability regulatory authority remove product market recall certain batch product national regulation phase prescription drug business price centralize food drug administration fda fda responsible protect public health assure safety efficacy security human veterinary drug biological product medical device generally free market pricing center medicare medicaid services cms medicare include provision price drug elderly disabled indigent receive federal prescription benefit scheringplough commit comply voluntary good practice pharmaceutical research manufacturers america phrma trade industry group member marketing advertising practice include scheringplough key market united kingdom france germany italy regulation local country level additional regulation level european medicine agency emea pharmaceutical product regulate level national mutual recognition centralized regulatory procedure emea coordinate evaluation table content supervision medicinal product paneu market pricing system individual member state systemsagencie regulate price local level japan regulation pharmaceutical medical device agency pmda pmda regulate pharmaceutical medical device development postmarketing use japanese government regulate pricingreimbursement pharmaceutical product japan complicated pricing process include benchmark price western country united states canada select country major country influence pricing cms united states increase pressure pharmaceutical industry bring product market provide differentiation versus exist product lead expensive scientifically challenging clinical trial order generate type datum new product versus market comparator raw material raw material essential scheringploughs operation available adequate quantity number potential supplier energy expect available scheringplough sufficient quantity meet operating requirement seasonality certain scheringplough product particularly respiratory sun care product seasonal nature seasonal pattern pronounce effect consolidated operation scheringplough environment date compliance federal state local law discharge material environment protection environment material effect scheringplough operation financial position employee december scheringplough employ approximately people worldwide available information scheringplough amendment report file furnish sec available free charge scheringplough website soon reasonably practicable material electronically file sec schering plough internet address wwwscheringploughcom scheringplough begin practice quarter report available scheringplough website hour filing report file scheringplough sec read copy secs public reference room street washington information operation public reference room obtain call sec sec sec maintain internet site wwwsecgov contain report proxy information statement information issuer file electronically sec item risk factor scheringplough future operating result cash flow differ materially result describe risk uncertaintie relate scheringploughs business include discuss addition factor represent risk uncertainty cause actual result differ materially imply forwardlooke statement contain report table content key scheringplough product generate significant scheringplough profit cash flow event adversely affect market lead product material negative impact result operation cash flow scheringplough ability generate profit operate cash flow depend largely continued profitability schering plough cholesterol franchise consist vytorin zetia addition key product remicade nasonex pegintron temodar clarinex avelox account material portion revenue result scheringploughs dependence key product event adversely affect market product significant impact result operation event include loss patent protection increase cost associate manufacture generic otc availability schering plough product competitive product discovery previously unknown effect increase competition introduction new effective treatment discontinuation removal market product reason example profitability scheringplough cholesterol franchise adversely affect competition multiple generic cholesterol product fda hold public meeting solicit comment make certain prescription drug available behindthe counter prescription continue study scenario fda indicate drug include category fda approve behindthecounter sale product compete product scheringplough merckschere plough cholesterol joint venture competition adverse result sale profitability high risk fund invest research generate financial return development novel drug require significant expenditure low probability success high rate failure inherent research develop new drug treat disease result high risk fund invest research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest scheringplough success dependent successful development marketing new product subject substantial risk product appear promise development fail reach market numerous reason include follow finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right intellectual property protection innovation important contributor scheringplough profitability generic form scheringplough product introduce market result expiration patent cover scheringploughs product successful challenge scheringploughs patent atrisk launch generic version scheringplough product material negative effect result operation intellectual property protection critical scheringplough ability successfully commercialize product patent relate scheringplough significant product material importance scheringplough expiration successful challenge scheringplough patent cover table content product competitor introduce lowerpriced generic similar branded version product include scheringplough wellestablishe product generic manufacturer file abbreviate new drug application seek approval expiration applicable datum exclusivity allege patent list innovator new drug application invalid infringe unenforceable allegation commonly know paragraph certification innovator ability file suit generic manufacturer enforce patent generic manufacturer paragraph certification extensively challenge patent wide array innovative pharmaceutical anticipate trend continue recent year generic manufacturer launch generic version product ultimate resolution patent litigation commonly know atrisk product launch generic entry result loss significant portion sale downward pressure price scheringplough offer patent product refer legal proceeding scheringplough description pende intellectual property litigation additionally certain foreign government indicate compulsory license patent grant case national emergency diminish eliminate sale profit region negatively affect scheringploughs result operation recent court decision relate company patent potential legislation relate patent reform regulatory initiative result erosion intellectual property protection patent dispute costly prosecute defend adverse judgment result damage award increase royalty similar payment decrease sale patent position highly uncertain patent dispute pharmaceutical industry unusual adverse result patent dispute involve scheringploughs patent patent collaborator lead determination court patent infringe invalid andor unenforceable adverse determination lead loss market exclusivity adverse result patent dispute involve patent hold party lead determination court patent infringe valid enforceable adverse determination preclude commercialization scheringplough product injunctive relief andor lead significant financial damage past ongoing infringement uncertainty surround patent litigation party settle patent dispute obtain license mutually agreeable term order decrease risk interruption manufacturing andor marketing product potential litigation scheringploughs intellectual property right exist initiate party attempt abridge scheringplough right scheringplough ultimately successful particular dispute scheringplough incur substantial cost defend patent intellectual property right patent challenge hatchwaxman act item legal proceeding list current paragraph certification scheringplough product multijurisdictional regulation include establish scheringploughs ability price product negatively affect scheringplough sale profit margin scheringplough face increase pricing pressure globally manage care organization institution government agency program negatively affect scheringplough sale profit margin example medicare prescription drug improvement modernization act contain prescription drug benefit individual eligible medicare prescription drug benefit effective january result increase use generic increase purchasing power negotiating behalf medicare recipient addition legislation concern price control trend affect scheringplough business trend include legislative regulatory action relate pharmaceutical pricing reimbursement health care reform initiative drug importation legislation involuntary approval medicine otc use trend include nongovernmental initiative practice consolidation customer manage care practice health care cost containment increasingly market approval table content reimbursement product prescriber practice policy party payor influence health technology assessment national institute health clinical excellence organization result government effort reduce medicaid expense manage care organization continue grow influence scheringplough face increase pricing pressure manage care organization continue seek price discount respect scheringplough product country governmental agency strictly control directly indirectly price pharmaceutical product sell market cost control method include restriction physician prescription level patient reimbursement emphasis great use generic drug acrosstheboard price cut decrease revenue internationally acquisition obs scheringplough acquire market product pipeline project therapeutic area currently cover scheringplough exist market product portfolio pipeline project include women health fertility anesthesia neuroscience carry unique risk uncertainty negative impact future result operation acquisition obs scheringplough acquire product additional therapeutic area therapeutic area present different risk profile include different benefit safety issue balance scheringplough regulator marketing decision unique product liability risk different patient prescriber priority different societal pressure add new therapeutic area strengthen business increase sale profit make combined company relevant patient prescriber diversify enterprise risk area positive outweigh additional risk particular therapeutic area result unanticipated cost material market force continue evolve impact scheringplough ability sell product price scheringplough charge product number intermediary involve drug manufacturer scheringplough patient use drug intermediary impact patient ability prescriber ability choose pay particular drug intermediary include health care provider hospital clinic payor representative employer insurer manage care organization government supply chain pharmacist wholesaler example include payor require patient fail generic drug reimburse effective brand product expensive hospital stock administer generic product inpatient manage care organization penalize doctor prescribe outside approve formulary include brand product generic available pharmacist receive large revenue dispense generic drug brand drug intermediary require routinely provide transparent data patient compare effectiveness generic brand product disclose economic benefit tie steering patient require patient use generic product brand product government investigation scheringplough lead commencement civil andor criminal proceeding involve imposition substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program rise investigation litigation government entity private party scheringplough predict future pende investigation subject lead judgment settlement involve significant monetary award restriction operation pricing sale marketing program arrangement relate business practice scheringplough participant health care industry increase scrutiny federal state regulatory investigative prosecutorial administrative entity entity include department table content justice attorney office office inspector general department health human service fda federal trade commission state attorney general office health care law certain governmental entity operate include federal state antikickback statute statutory common law false claim law construe broadly court permit government entity exercise significant discretion event governmental entity believe wrongdoing occur institute civil criminal proceeding resolve unfavorably subject scheringplough substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program addition adverse outcome government investigation prompt government entity commence investigation scheringplough cause entity private party bring civil claim scheringplough predict investigation affect marketing practice sale result material adverse impact schering plough result operation cash flow financial condition business congress certain state initiate investigation time disclosure enhance clinical trial relate event time certain stock sale executive officer carrie cox regardless merit outcome investigation government investigation costly divert management attention scheringplough business result substantial damage scheringplough reputation legal matter adverse outcome negatively affect scheringplough business unfavorable outcome pende litigation matter future litigation include litigation concern product pricing security law violation product liability claim erisa matter patent intellectual property dispute antitrust matter preclude commercialization product negatively affect profitability exist product subject scheringplough substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program result materially adversely affect scheringploughs result operation cash flow financial condition business refer legal proceeding item description significant pende litigation issue concern merckscheringplough cholesterol joint venture enhance clinical trial material adverse effect joint venture sale vytorin zetia turn material adverse impact scheringplough financial condition item legal proceeding enhance matter background information merckscheringplough cholesterol join ventures enhance clinical trial relate matter issue concern merckscheringplough cholesterol joint venture enhance clinical trial material adverse effect merckscheringplough cholesterol joint venture sale vytorin zetia significant negative medium surround release topline result date im data show prescription vytorin zetia decline sale product continue trend remain current level prolong period scheringplough business cash flow result operation financial position prospect materially adversely affect addition unfavorable outcome result government investigation litigation concern sale promotion product material adverse effect scheringplough financial position liquidity result operation table content scheringplough subject governmental regulation failure comply cost compliance regulation adversely affect scheringplough financial position result operation scheringplough manufacture facility clinicalresearch practice meet stringent regulatory standard subject regular inspection cost regulatory compliance include associate compliance failure materially affect schering plough financial position cash flow result operation failure comply regulation include pharmacovigilance reporting requirement standard relate clinical laboratory manufacturing practice result delay approval drug seizure recall drug suspension revocation authority necessary production sale drug fine civil criminal sanction scheringplough subject regulation include environmental health safety labor regulation development follow regulatory approval adversely affect sale scheringplough product product reaches market certain development follow regulatory approval include result postmarkete phase trial decrease demand scheringplough product include follow rereview product market new scientific information evolution scientific theory recall loss marketing approval product market uncertainty concern safety labeling change great scrutiny advertising promotion past year clinical trial postmarkete surveillance certain market drug competitor industry raise safety concern lead recall withdrawal adverse labeling market product situation raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition increase scrutiny outcome clinical trial lead increase volatility market reaction addition follow wake recent product withdrawal company significant safety issue health authority fda european medicine agency pharmaceutical medicine device agency increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication rereviewe select product market add uncertainty regulatory process great regulatory scrutiny especially advertising promotion particular directtoconsumer advertising previously unknown effect discover increase prevalence negative publicity know effect scheringplough product significantly reduce demand product require scheringplough remove product market current environment pharmaceutical company operate scheringplough risk product liability claim product new product technological advance develop scheringploughs competitor negatively affect sale scheringplough operate highly competitive industry scheringplough compete large number multinational pharmaceutical company biotechnology company generic pharmaceutical company scheringploughs competitor conduct research development area serve scheringplough current product product scheringplough process table content develop competitive development impact scheringplough include technological advance patent grant new product develop competitor new exist generic prescription andor otc product compete product schere plough merckscheringplough cholesterol joint venture addition possible doctor patient provider favor product offer competitor safety efficacy pricing reimbursement characteristic result scheringplough unable maintain sale product competition party difficult scheringplough acquire license new product product candidate regardless stage development enter transaction term permit scheringplough generate positive financial impact scheringplough depend acquisition inlicense arrangement source new product opportunity obtain license new product limit secure right typically require substantial amount fund substantial resource commitment scheringplough compete opportunitie company party great financial resource great ability resource commitment scheringplough able acquire license new product adversely impact scheringplough prospect scheringplough difficulty acquire license new product acceptable term secure right new product scheringplough substantial financial resource commitment limit ability produce positive financial impact transaction scheringplough rely thirdparty relationship key product conduct change circumstance party adversely impact business scheringplough relationship party scheringplough depend key product party compete scheringplough interest align interest scheringplough notwithstanding contract scheringplough party scheringplough able control influence conduct party circumstance affect adversely impact scheringplough relationship longstanding party work scheringplough work evolve priority alignment change time new issue develop anticipate time contract negotiate new issue relate uncertainty contract adversely impact scheringplough scheringplough global operation expose scheringplough additional risk adverse event material negative impact result operation majority scheringplough operation outside acquisition obs late scheringploughs global operation human prescription pharmaceutical animal health increase acquisition recently complete purchase obs expand size scale scope global operation risk inherent conduct global business include change medical reimbursement policy program price restriction key market multiple regulatory requirement restrict scheringploughs ability manufacture sell product key market trade protection measure import export licensing requirement diminish protection intellectual property country possible nationalization expropriation addition change scheringplough business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease table content integration business scheringplough obs create combine company complex process subject unforeseen development impact anticipate cost saving synergy expect accretion earning result future operation company combine workforce scheringplough obs continue face uncertainty completion integration phase substantial effort complete integration phase quickly possible difficult predict long integration phase workforce company learning use new process work integrate streamlined employee new combine company past work usbased global company applicable regulatory requirement different number respect substantial effort facilitate smooth execution integration include thorough training transparent motivational employee communication increase risk slow execution work process repeat execution achieve quality standard reputational harm event compliance failure new complex regulatory requirement failure inadvertent event adverse impact anticipate cost saving synergy anticipate accretion earning transaction result future operation acquisition obs expand scheringploughs animal health business worldwide increase risk negative event animal health industry negative impact future result operation acquisition obs animal health business scheringplough global animal health business significant business segment combine company future sale key animal health product adversely impact number risk factor include certain specific animal health business example outbreak disease carry animal bovine spongiform encephalopathy bse mad cow disease lead widespread death precautionary destruction reduce consumption demand animal adversely impact scheringploughs result operation outbreak highly contagious disease near scheringplough main production site require scheringplough immediately halt production vaccine site force scheringplough incur substantial expense procure raw material vaccine animal health segment scheringplough business significant impact event future result operation significant acquisition obs increase scheringplough biologics human animal health product offering include animal health vaccine biologic carry unique risk uncertainty negative impact future result operation successful development testing manufacturing commercialization biologic particularly human animal health vaccine long expensive uncertain process unique risk uncertaintie biologic include limited access supply normal diseased tissue sample cell line pathogen bacteria viral strain biological material addition government regulation multiple jurisdiction european state result restrict access transport use material scheringplough lose access sufficient source material tight restriction impose use material scheringplough able conduct research activity plan incur additional development cost development manufacturing marketing biologic subject regulation fda european medicines agency regulatory body regulation complex extensive regulation applicable pharmaceutical product example biologic license application include preclinical clinical trial datum extensive datum manufacturing procedure require human vaccine candidate fda approval release manufacture lot table content manufacturing biologic especially large quantity complex require use innovative technology handle living microorganism manufacturing biologic require facility specifically design validate purpose sophisticated quality assurance quality control procedure necessary slight deviation manufacturing process include fill labeling packaging storage shipping quality control testing result lot failure product recall spoilage biologic frequently costly manufacture production ingredient derive live animal plant material biologic synthetically particular keeping demand vaccine difficult complexity produce vaccine use biologically derive ingredient lead allegation harm include infection allergic reaction closure product facility possible contamination event result substantial cost scheringplough expose market risk fluctuation currency exchange rate interest rate scheringplough operate multiple jurisdiction virtually sale denominate currency local jurisdiction additionally scheringplough enter enter acquisition licensing borrowing financial transaction rise currency interest rate exposure scheringplough certainty foresee mitigate adverse fluctuation fluctuation currency exchange rate interest rate negatively affect scheringploughs result operation andor cash flow order mitigate adverse impact market fluctuation scheringplough time time enter hedge agreement hedge agreement currency option interest rate swap limit exposure exchange rate interest rate fluctuation attempt mitigate risk costly successful insurance coverage product liability limit cost prohibitive unavailable scheringplough maintain insurance coverage deductible selfinsurance reflect market condition include cost availability exist time write relationship insurance coverage selfinsurance vary accordingly certain product thirdparty insurance cost prohibitive available limited term unavailable scheringplough subject evolve complex tax law result additional liability affect result operation scheringplough subject evolve complex tax law jurisdiction significant judgment require determine schering plough tax liability scheringplough tax return periodically examine tax authority scheringplough tax return remain open examination irs scheringplough challenge irs tax authority position take income tax return scheringplough believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue acquisition obss organon human pharmaceutical intervet animal health business main tax risk correspondingly center netherlands management intellectual property beneficial right product liability predominantly center tax position organon intervet netherlands closed addition scheringplough impact change tax law include tax rate change change law relate remittance foreign earning new tax law revise tax law interpretation domestic foreign jurisdiction table content item unresolved staff comment item property scheringplough corporate global human pharmaceutical headquarters locate kenilworth new jersey animal health global headquarters locate boxmeer netherland principal research facility locate kenilworth union summit new jersey palo alto california nebraska animal health principal research facility outside locate netherlands scotland principal manufacturing facility follow location product type belgium pharmaceutical brazil pharmaceuticals animal health cleveland tennessee usa consumer product france pharmaceuticals ireland pharmaceutical consumer product animal health kenilworth new jersey usa pharmaceuticals consumer product mexico pharmaceutical millsboro delaware usa animal health netherlands pharmaceuticals animal health omaha nebraska usa animal health puerto rico pharmaceuticals research triangle park north carolina usa pharmaceuticals singapore pharmaceuticals scheringplough own majority property general property adequately maintain suitable purpose discuss detail certain scheringplough manufacturing site operate capacity scheringplough currently process build pharmaceutical sciences center new jersey capital expenditure approximately million million respectively relate center additional capital expenditure approximately million expect year item legal proceeding material pende legal proceeding ordinary routine litigation incidental business scheringplough corporation subsidiary property subject disclose additional information legal proceeding include important financial information find litigation charge discussion item management discussion analysis financial condition result operation note special acquisition relate charge manufacture streamlining note legal environmental regulatory matter contain item financial statement supplementary datum enhance matter background merckscheringplough cholesterol joint venture market zetia vytorin combination merck zocor simvastatin scheringploughs zetia ezetimibe merckscheringplough cholesterol joint venture enhance effect combination ezetimibe highdose simvastatin simvastatin atherosclerotic process patient heterozygous familial hypercholesterolemia clinical trial surrogate endpoint trial conduct patient table content heterozygous familial hypercholesterolemia rare condition affect approximately population primary endpoint mean change intimamedia thickness measure site carotid artery right leave common carotid internal carotid carotid bulb patient treat ezetimibesimvastatin versus patient treat simvastatin twoyear period statistically significant difference treatment group primary endpoint component primary endpoint include common carotid artery key secondary imaging endpoint show statistical difference treatment group january merckscheringplough cholesterol joint venture announce topline result enhance clinical trial fuller discussion result enhance clinical trial medical scientific forum customary discussion schedule american college cardiology meeting march technical difficulty analyze fuzzy ultrasound image consume long time period patient scan april december datum ultrasound image unblinde scientist merckscheringplough cholesterol joint venture analysis result summary finding release joint venture january medium speculation length time need analyze ultrasound image medium confusion mean trial result medical expert health advisory group long recognize high ldl cholesterol significant cardiovascular risk factor recommend increasingly aggressive treatment high cholesterol certain patient lower ldl cholesterol healthy diet lifestyle change remain cornerstone lipid treatment patient risk heart disease clinical study prior enhance demonstrate vytorin lower patient ldl cholesterol rosuvastatin atorvastatin simvastatin dose study able patient ldl cholesterol goal define atp iii finding merckscheringplough cholesterol joint venture enhance clinical trial confirm vytorin effectiveness compare simvastatin lower ldl cholesterol specifically significant difference lowdensity lipoprotein ldl cholesterol lower see treatment group ldl cholesterol lower month ezetimibesimvastatin compare month simvastatin enhance surrogate endpoint study power design assess cardiovascular clinical event outcome effectiveness drug lower risk heart attack stroke merckscheringplough cholesterol joint venture currently conduct improveit trial large clinical trial compare vytorin ezetimibesimvastatin simvastatin patient result improveit trial compare effectiveness vytorin simvastatin reduce heart attack andor stroke scheringplough stock price decline significantly early closing price december low closing price january closing price february day file investigation date file scheringplough joint venture andor joint venture partner merck inc merck receive letter congress include house committee energy commerce house subcommittee oversight investigation rank minority member senate finance committee collectively seek combination witness interview document information variety issue relate merckscheringplough cholesterol joint venture enhance clinical trial company sale promotion vytorin sale stock table content company corporate officer include executive scheringplough name letter carrie cox april subpoena state official state attorney general state department justice state include connecticut new york oregon seek similar information document scheringplough cooperating investigation work merck respond inquiry litigation addition midjanuary scheringplough aware serve litigation include civil class action lawsuit allege common law state consumer fraud claim connection scheringplough sale promotion merckscheringplough jointventure product vytorin zetia putative shareholder security class action lawsuit officer name defendant allege false misleading statement omission scheringplough representative relate timing disclosure concern enhance result allegedly violation section securities exchange act shareholder derivative action allege board director breach fiduciary obligation relate timing release enhance result letter behalf single shareholder request board director investigate allegation putative security class action warrant bring appropriate legal action behalf scheringplough scheringplough cooperate fully government investigation intends vigorously defend lawsuit file relate enhance study patent matter describe patent trademark intellectual property right item business intellectual property protection critical scheringplough ability successfully commercialize product innovation potential litigation scheringploughs intellectual property right exist initiate party attempt abridge scheringplough right scheringplough protect right patent matter describe potential material effect schere plough scholl freeze away july orasure technology file action district court eastern district pennsylvania allege patent infringement scheringplough healthcare product sale scholl freeze away wart removal product matter settle material impact scheringplough financial statement stipulation dismiss action file party february patent challenge hatchwaxman act scheringplough currently believe pende paragraph certification proceeding hatchwaxman act material frequently medium investor interest proceeding scheringplough list pende proceeding quarter currently follow pende july scheringplough licensor cancer research technology limit file patent infringement action company seek approval generic version certain strength temodar capsule march scheringplough entity jointly own merck file patent infringement action company seek approval generic version zetia september date scheringplough file patent infringement action company seek approval generic version clarinex tablets clarinex reditab clarinex clarinex table content awp litigation investigation scheringplough continues respond exist new litigation certain state private payor investigation department health human services department justice state industry scheringplough practice average wholesale price awp scheringplough cooperating investigation litigation investigation relate awp pharmaceutical company certain drug improperly exceed average price pay provider consequence result unlawful inflation certain reimbursement drug state program private payor base awp complaint allege violation federal state law include fraud medicaid fraud consumer protection violation claim majority case plaintiff seek class certification case class certify outcome litigation investigation include substantial damage imposition substantial fine penalty injunctive administrative remedy security class action litigation federal security litigation follow scheringploughs announcement fda conduct inspection scheringplough manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice lawsuit file scheringplough certain name officer lawsuit allege defendant violate federal security law allegedly fail disclose material information make material misstatement specifically allege schering plough fail disclose allege risk new drug application clarinex delay result manufacturing issue allege scheringplough fail disclose allege depth severity manufacturing issue complaint consolidate action district court district new jersey consolidated amend complaint file october purport represent class shareholder purchase share scheringplough stock february complaint seek compensatory damage behalf class court certify shareholder class october notice pendency class action send member class july discovery complete motion summary judgment brief pende erisa litigation march scheringplough serve putative class action complaint file district court new jersey allege scheringplough retire chairman ceo president richard jay kogan scheringploughs employee saving plan plan administrator current director certain corporate officer messrs larosa moore breach fiduciary obligation certain participant plan complaint seek damage loss allegedly suffer plan complaint dismiss june plaintiff appeal august court appeal circuit reverse dismissal district court matter remand district court proceeding kdur antitrust litigation scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle relate generic version kdur scheringploughs longacte potassium chloride product supplement cardiac patient lederle upsher smith file abbreviate new drug application follow commencement ftc administrative proceeding allege anti competitive effect settlement resolve scheringplough favor allege class action suit file federal state court behalf direct indirect purchaser kdur scheringplough upshersmith lederle suit claim violation federal state antitrust law table content state statutory common law cause action suit seek unspecified damage discovery ongoing thirdparty payor action purport class action litigation file follow announcement settlement massachusetts investigation plaintiff action seek damage behalf thirdparty payor result allegation offlabel promotion improper payment physician issue massachusetts investigation tax matter october irs auditor assert interest rate swap scheringplough enter unrelated party recharacterize loan affiliate company result additional tax liability tax year september scheringplough payment irs million income tax million interest scheringplough file refund claim tax interest irs december follow irss denial scheringplough claim refund scheringplough file suit district court district new jersey refund tax interest refund litigation currently try newark district court scheringplough tax reserve adequate cover abovementione payment pende administrative obligation connection settlement investigation department justice attorney office eastern district pennsylvania scheringplough enter fiveyear corporate integrity agreement cia cia amend august connection settlement massachusetts investigation commence new fiveyear term failure comply obligation cia result financial penalty matter product liability beginning number complaint file jurisdiction assert claim organon usa inc organon pharmaceuticals usa inc andor organon international organon arise scheringplough marketing sale nuvare combine hormonal contraceptive vaginal ring plaintiff contend organon fail adequately warn allege increase risk venous thromboembolism vte pose nuvare andor downplay risk vte plaintiff seek damage heart attack stroke majority case currently pende united states district court district new jersey case pende wisconsin missouri new york georgia french matter base complaint french competition authority competitor france pursuant court order french competition authority obtain document french subsidiary scheringplough relate subutex product subsidiary market sell resolution matter adverse french subsidiary result imposition civil fine injunctive administrative remedy july juge des libert dtention order annulment search seizure procedural ground july french authority appeal order french supreme court april competitor request interim relief portion grant french competition authority december interim relief require scheringploughs french subsidiary publish specialized newspaper information include generic quantitative qualitative composition pharmaceutical form substitutable subutex february paris court appeal confirm decision french competition authority table content item submission matter vote security holder applicable executive officer registrant list executive officer corporate officer scheringplough february indicate hold position indicate past year officer serve year successor duly appoint title robert bertolini executive vice president chief financial officer john carroll vice president global internal audits ron cheeley senior vice president global human resource carrie cox executive vice president president global pharmaceuticals william creelman vice president tax fred hassan chairman chief executive officer steven koehler vice president controller thomas koestler phd executive vice president president scheringplough research institute raul kohan senior vice president corporate excellence joseph larosa vice president legal affair ian mcinne senior vice president president global supply chain kevin moore vice president treasurer lori queisser senior vice president global compliance business practice thomas sabatino executive vice president general counsel karl salnoske vice president chief information officer brent saunder senior vice president president consumer health care corporate secretary associate general counsel vice president corporate susan ellen wolf governance officer define rule securities exchange act bertolini join scheringplough executive vice president chief financial officer bertolini partner pricewaterhousecoopers carroll join scheringplough vice president global internal audits carroll vice president general auditor american standard company general auditor american standard company assistant treasurer bristolmyer squibb cheeley join scheringplough senior vice president global human resources cheeley group vice president global compensation benefit pharmacia corporation cox join scheringplough executive vice president president global pharmaceuticals cox executive vice president president global prescription business pharmacia corporation creelman join scheringplough vice president tax creelman senior tax counsel pfizer creelman assistant vice president international tax cigna corporation table content hassan join scheringplough chairman board chief executive officer hassan chairman board chief executive officer pharmacia corporation koehler join scheringplough vice president controller koehler senior vice president chief financial officer treasurer vice president chief financial officer treasurer corporate secretary medicine company koestler name executive president president scheringplough research institute september koestler executive vice president global development scheringplough research institute september executive vice president scheringplough research institute senior vice president global regulatory affair pharmacia corporation larosa vice president legal affair larosa staff vice president secretary associate general counsel mcinne join scheringplough senior vice president global supply chain mcinne senior vice president global supply chain pharmacia corporation executive vice president supply chain watson pharmaceuticals inc queisser join scheringplough february senior vice president global compliance business practice queisser vice president chief compliance officer october february executive director general auditor march october eli lilly company sabatino join scheringplough executive vice president general counsel sabatino senior vice president general counsel baxter international inc salnoske join scheringplough vice president chief information officer salnoske ceo adaptive trade saunder join scheringplough senior vice president global compliance business practice saunders partner pricewaterhousecooper wolf name vice president corporate secretary associate general counsel hold position scheringplough law department item market registrant common equity relate stockholder matter principal market scheringplough common stock new york stock exchange additional information require item incorporate reference table caption quarterly datum unaudite item financial statement supplementary data table content follow table provide information respect purchase scheringplough common share fourth quarter issuer purchase equity security total number aximum number share purchase share average publicly purchase total number price pay announce plan plan period share purchase share program programs october october november november december december total october december share include table repurchase pursuant scheringploughs stock incentive program represent share deliver scheringplough option holder payment exercise price tax withholding obligation connection stock option stock award performance graph comparison cumulative total return year end december scheringplough corporation composite peer group index graph assume investment december reinvestment dividend scheringplough common share index composite peer group major usbased pharmaceutical company abbott laboratories bristolmyers squibb company johnson johnson eli lilly company merck inc pfizer inc wyeth table content item select financial datum million share figure percentage operate result net sale equity income lossincome income taxis net lossincome net lossincome available common shareholder dilute lossearning common share basic lossearning common share research development expense acquire inprocess research development depreciation amortization expense financial position cash flow property net total asset longterm debt shareholder equity capital expenditure financial statistic net lossincome percent net sale return average shareholder equity net book value common share datum cash dividend common share cash dividend pay common share cash dividend prefer share average share outstanding calculate dilute earningsloss common share average share outstanding calculate basic earningsloss common share common share outstanding yearend operating result financial information reflect close obs acquisition november include impact purchase accounting accordance sfas business combination include special acquisition relate charge manufacture streamlining cost respectively note special acquisition relate charge manufacture streamline additional information charge incur special charge incur include million employee termination cost million asset impairment relate charge special charge include increase litigation reserve million result investigation scheringplough sale marketing practice approximately million employee termination cost relate voluntary early retirement program announce august million asset impairment charge increase longterm debt primarily reflect finance obs acquisition table content assume conversion mandatory convertible preferred stock approximately million common share assume conversion mandatory convertible preferred stock approximately million common share million common share million common share item management discussion analysis financial condition result operation executive summary overview scheringplough scheringplough innovationdriven sciencecentere global health care company scheringplough discover develop manufacture pharmaceutical customer market human prescription animal health consumer research development activity direct prescription product important application central research development platform animal health product consumer health care product scheringplough access external innovation partner inlicense acquisition customer market strategy focus science early decade scheringplough experienced number business regulatory legal challenge april board director name fred hassan new chairman board chief executive officer scheringplough corporation support board initiate strategic plan goal stabilize repair turn scheringplough order build longterm shareholder value instal new senior executive team strategic plan action agenda eightyear fivephase plan scheringplough currently fourth phase action agenda build base build base phase scheringplough continue focus strategy value creation broad believe organon bioscience obs acquisition major transformative accomplishment regard obs acquisition add diversification market product include new therapeutic area women health central nervous system significant strength animal health product pipeline accomplishment include grow business example double digit sale growth product group human pharmaceutical animal health consumer health care penetrate new market include china brazil russia expand product portfolio scheringplough customer group human pharmaceutical animal health consumer health care discover develop acquire new product key component action agenda apply science meet unmet medical need research development activity focus mechanism treat disease result core strategy scheringplough invest substantial fund scientific research goal create therapy treatment address important unmet medical need commercial value scheringplough successful advance pipeline latestage project require sizable resource complete consistent core strategy scheringplough increase investment research development scheringplough continue develop late phase growthdriver pipeline sugammadex thrombin receptor antagonist golimumab vicriviroc boceprevir asenapine anticipate high spending clinical trial activity scheringplough progress early pipeline include drug candidate wide range therapeutic area compound approach phase development action agenda scheringplough continue work enhance infrastructure upgrade process system strengthen talent recruitment talented individual development key employee effort implement companywide basis scheringplough focus especially research development support scheringplough sciencebase business table content integration ob employee scheringplough new talent add addition integration obs scheringplough announce workforce reduction eliminate redundancy result highlight scheringplough performance follow closed acquisition obs november purchase price approximately euro billion scheringplough net sale billion increase billion percent compare period net sale include million sale product acquire obs acquisition net loss available common shareholder billion compare net income available common shareholder billion include net loss approximately billion charge relate purchase accounting obs acquisition include billion acquire inprocess research development charge cash flow provide operating activity billion global sale scheringplough cholesterol franchise product vytorin zetia cholesterol joint venture merck company inc merck continue grow contribute significantly scheringplough improve operating result cash flow note development addition increase sale pharmaceutical product remicade temodar nasonex contribute favorably scheringplough overall operating result cash flow additional strength scheringplough develop year hassan new management team begin action agenda key scheringplough current environment pharmaceutical industry continue subject evermore critical scrutiny event mischaracterize drive amplify reaction scheringplough believe new scientific datum well present discuss appropriate scientific medical forum early development relate cholesterol franchise explain detail item legal proceeding enhance matter early scheringplough encounter challenge result merckscheringplough cholesterol joint venture clinical trial call enhance joint venture product zetia vytorin subject media scrutiny prior fuller discussion trial result appropriate medical forum discussion schedule american college cardiology meeting march medical expert health advisory group long recognize high ldl cholesterol know bad cholesterol significant cardiovascular risk factor recommend increasingly aggressive treatment high cholesterol certain patient lower ldl cholesterol healthy diet lifestyle change remain cornerstone lipid treatment patient risk heart disease clinical study include enhance demonstrate vytorin lower patient ldl cholesterol rosuvastatin atorvastatin simvastatin dose study able patient ldl cholesterol goal define atp iii early tell impact joint venture enhance trial result joint venture cholesterol business schering plough diversify group product geographic area highly experienced executive team give scheringplough additional strength helpful weather situation strategic alliance typical pharmaceutical industry scheringplough license manufacturing marketing andor distribution right certain product manufacture market andor distribute product table content own pursuant license joint venture arrangement time party involve additional factor relate party outside control scheringplough create positive negative impact scheringplough vytorin zetia remicade subject arrangement key scheringplough current business financial performance addition potential strategic alternative impact change control provision arrangement result vytorin zetia acquire merck remicade revert centocor change control provision relate vytorin zetia include contract merck file exhibit scheringploughs change control provision relate remicade contain contract centocor file exhibit scheringploughs cholesterol franchise scheringploughs cholesterol franchise product vytorin zetia manage joint venture scheringplough merck treatment elevate cholesterol level market outside japan zetia scheringplough novel cholesterol absorption inhibitor vytorin combination zetia zocor simvastatin statin medication develop merck financial commitment compete cholesterol reduction market share merck profit sale vytorin zetia share merck operating result joint venture merck record equity method accounting cholesterolreduction market single large pharmaceutical category world vytorin zetia compete market combine basis product continue grow term sale market share note development material change sale market share scheringplough cholesterol franchise significant impact scheringplough consolidated result operation cash flow order maintain enhance infrastructure business scheringplough continue increase profit increase profitability largely dependent performance scheringplough cholesterol franchise japan include joint venture merck japanese market bayer healthcare comarketing scheringploughs cholesterolabsorption inhibitor zetia approve japan april monotherapy coadministere statin use patient hypercholesterolemia familial hypercholesterolemia homozygous sitosterolemia zetia launch japan june scheringploughs sales zetia japan comarkete agreement bayer healthcare recognize net sale license arrangement centocor remicade prescribe treatment inflammatory disease rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylose spondylitis plaque psoriasis ulcerative colitis remicade scheringplough second large market pharmaceutical product line cholesterol franchise remicade license manufactured centocor inc johnson johnson company scheringplough exercise option contract centocor license right develop commercialize golimumab fully human monoclonal antibody currently phase iii trial scheringplough exclusive marketing right product outside japan certain asian market december scheringplough centocor revise distribution agreement development commercialization distribution remicade golimumab extend schering plough right exclusively market remicade match duration scheringplough exclusive marketing right golimumab effective regulatory approval golimumab scheringploughs marketing right product extend year commercial sale golimumab centocor receive progressively increase share profit scheringplough distribution product scheringplough marketing territory share profit remain fixed remainder term change duration remicade marketing right profit share arrangement product condition approval golimumab grant prior september scheringplough independently develop table content market golimumab crohns disease indication territory option centocor participate addition scheringplough centocor agree utilize autoinjector device commercialization golimumab agree share development cost right device scheringplough upfront payment million include research development expense year end december manufacturing sale marketing scheringplough support commercialize product manufacturing sale marketing effort scheringplough move forward additional investment enhance infrastructure business include capital expenditure drug development process product move drug discovery pipeline market information technology system postmarkete study monitor scheringplough continually review business include manufacturing operation identify action enhance longterm competitiveness scheringplough manufacturing cost base relatively fix action significantly reduce scheringploughs manufacturing infrastructure include obs manufacturing operation acquire involve complex issue result shift product manufacturing plant year construction regulatory requirement include revalidation registration requirement time time action take enhance scheringplough overall manufacture efficiency example scheringplough closed manufacturing plant puerto rico begin process close small manufacturing facility asia pacific region scheringplough continue review carry value manufacture asset indication impairment future event decision lead additional asset impairment relate cost regulatory competitive environment scheringplough subject jurisdiction national state local regulatory agency regulatory compliance complex costly impact timing need bring new drug market market drug new indication scheringplough engage clinical trial research country world research activity comply stringent regulatory standard subject inspection local country regulatory authority scheringplough subject pharmacovigilance reporting requirement country jurisdiction include member states clinical trial postmarkete surveillance certain market drug competitor industry raise safety concern lead recall withdrawal adverse labeling market product number intermediary involve drug manufacturer scheringplough patient use drug intermediary impact patient ability precriberss ability choose pay particular drug intermediary include health care provider hospital clinic payor representative employer insurer manage care organization government supply chain pharmacist wholesaler scheringploughs pharmaceutical product subject increasingly competitive pricing certain intermediary include manage care group institutions government agency seek price discount international market scheringplough operate environment government mandate costcontainment program price sale marketing program arrangement relate business practice scheringplough participant health care industry increase scrutiny federal state regulatory investigative prosecutorial administrative entity market pharmaceutical product competitive scheringplough operation affect technological advance competitor industry consolidation patent grant competitor loss patent protection challenge competitor competitive combination product new product competitor new information clinical trial market product postmarkete surveillance generic competition scheringplough product mature table content obs acquisition november scheringplough acquire obs purchase price approximately euro billion cash approximately billion commencing acquisition date obs asset acquire liability assume result obs operation include scheringplough consolidated financial statement approximately onehalf month result operation relate obs include scheringplough statement consolidated operation year end december impact purchase accounting base preliminary valuation result follow noncash charge acquire inprocess research development iprd onetime charge approximately billion amortization inventory adjust fair value approximately billion charge cost sale million approximately year period acquisition date amortization acquire intangible asset adjust fair value billion amortize weight average life year cost sale million incremental depreciation relate adjustment fair value property plant equipment million depreciate primarily cost sale live applicable property million billion acquire iprd charge associate research project womens health central nervous system anesthesia therapeutic area human health research project animal health determine discount cash flow projection identify research project technological feasibility establish alternative future use discount rate range percent percent project launch date follow fda regulatory approval year time scheringplough expect project begin generate cash flow research development project consider valuation subject normal risk uncertainty associate demonstrate safety efficacy require obtain fda regulatory approval discussion operating result result operation discuss include obs product sale expense certain noncash charge relate purchase accounting associate obs acquisition net sale significant portion net sale major pharmaceutical health care product distributor major retail chain consequently net sale quarterly growth comparison affect fluctuation buy pattern major distributor retail chain trade buyer fluctuation result seasonality pricing wholesaler retail trade buying decision change overall demand factor factor addition fluctuation sale pharmaceutical product subject increase pricing pressure manage care group institution government agency group seek discount scheringplough pharmaceutical manufacturer market require provide statutorily define rebate government agency order participate medicaid program veterans health care program governmentfunde program medicare prescription drug improvement modernization act contain prescription drug benefit individual eligible medicare prescription drug benefit effective january result increase use generic increase purchasing power negotiating behalf medicare recipient international market scheringplough operate environment government mandate costcontainment table content program place restriction physician prescription level patient reimbursement emphasize great use generic drug enact acrosstheboard price cut method control cost consolidate net sale billion increase billion percent compare consolidated net sale include million ob net sale relate period subsequent acquisition increase reflect growth sale volume remicade temodar nasonex avelox contribution animal health consumer health care favorable impact percent foreign exchange consolidate net sale billion increase billion percent compare increase primarily reflect growth sale volume remicade nasonex pegintron temodar increase reflect unfavorable impact percent foreign exchange net sale year end december follow incre ase dec rease dollar million human prescription pharmaceutical remicade nasonex pegintron temodar clarinexaerius claritin avelox integrilin rebetol caelyx intron subutexsuboxone asmanex pharmaceutical animal health consumer health care otc foot care sun care consolidate net sale meaningful percentage sale human prescription pharmaceutical total billion billion increase compare include million net sale relate organon human health business obs sale human prescription pharmaceutical total billion billion increase compare international net sale remicade drug treatment immunemediate inflammatory disorder rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylose spondylitis plaque psoriasis ulcerative colitis percent billion compare drive continued market growth expand use indication favorable impact foreign table content exchange global net sale increase percent billion compare great demand expand indication continue market growth competitive product indication refer introduce global net sale nasonex nasal spray oncedaily corticosteroid nasal spray allergy rise percent billion compare increase sale geographic region percent million compare product capture great international market share competitive product introduce global net sale pegintron powder injection pegylate interferon product treat hepatitis increase percent million compare high sale latin america emerge market europe temper low sale japan increase competition decrease market size global net sale increase percent million compare reflect high sale volume japan japan sale benefit significant number patient wait approval pegintron begin treatment global net sale temodar capsule treatment certain type brain tumor increase percent million compare increase sale geographic market include japan product launch september global net sale increase percent million compare increase utilization new indication global net sale clarinex market aerius country outside treatment seasonal outdoor allergy yearround indoor allergy increase percent million compare primarily high sale international market global net sale increase percent million compare increase demand europe latin america increase sale despite slightly decline market share international net sale prescription claritin increase percent million compare reflect growth latin america asia pacific japan sale decrease percent million compare net sale avelox fluoroquinolone antibiotic treatment certain respiratory skin infection sell primarily scheringplough result license agreement bayer increase percent million compare primarily result increase market share net sale increase percent million compare million share growth new indication global net sale integrilin injection glycoprotein platelet aggregation inhibitor treatment patient acute coronary syndrome sell primarily scheringplough increase percent million compare sale increase percent million compare global net sale rebetol capsule use combination pegintron intron treat hepatitis decrease percent million compare lower patient enrollment japan increase generic competition global net sale decrease percent million compare low sale europe increase competition japan sale benefit significant number patient wait approval pegintron begin hepatitis treatment international net sale caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma increase percent million compare primarily increase sale latin america favorable impact foreign exchange sale increase percent million compare primarily expand market product global net sale intron injection chronic hepatitis antiviral anticancer indication decrease percent million compare percent table content million compare decrease conversion pegintron treat hepatitis japan international net sale subutexsuboxone treatment opiate addiction increase percent million compare result benefit foreign exchange sale increase percent million compare increase market share october suboxone approve include member state iceland norway treatment opioid dependence global net sale asmanex orally inhale steroid asthma percent million compare primarily market share growth sale increase million compare asmanex launch commence late pharmaceutical net sale include net sale organon date acquisition december large number low sale volume human prescription pharmaceutical product net sale organon million include million follistimpuregon fertility treatment million nuvare contraception product include pharmaceutical sale low volume product sell limited market outside multiple source product long protect patent product include treatment respiratory cardiovascular dermatological infectious oncological disease include pharmaceutical sale sale scheringplough albuterol product fda issue final rule require cfc albuterol product include scheringplough proventil cfc remove market later december scheringploughs transition albuterol hfa proventil hfa complete scheringplough long manufacture cfc product remain cfc inventory sell scheringplough uncertain ultimate impact scheringplough overall future sale proventil hfa complexity multiple external factor influence transition include compete albuterol hfa product global net sale animal health product increase percent billion compare include global animal health net sale million relate intervet animal health business obs period subsequent acquisition global net sale benefit solid growth geographic area lead cattle companion animal product line couple positive impact foreign currency exchange rate global net sale increase percent million compare reflect strong growth core brand geographic specie area lead high sale companion animal product animal health segment sale growth rate impact intense competition frequent introduction generic product global net sale consumer health care product include otc foot care sun care product increase percent million compare increase primarily sale miralax launch february rxtootc switch laxative category year high sale otc claritin global net sale increase percent million compare reflect increase sale sun care product scholl foot care product sale otc claritin increase percent million compare sale growth product form otc claritin sale decrease percent compare result restriction retail sale otc product contain pseudoephedrine pse addition otc claritin continue face competition private label brand loratadine compete prescription antihistamine launch otc sale early net sale sun care product increase million percent compare coppertone continuous spray line extension million percent compare primarily success new coppertone continuous spray product launch future sale consumer health care segment difficult predict consumer health care market highly competitive heavy advertising consumer frequent competitive product introduction table content cost expense equity income summary cost expense equity income year end december follow incre dec rease dollar millions gross margin sell general administrative sga research development acquire inprocess research development iprd incomeexpense net special acquisitionrelate charge equity income meaningful percentage substantially sale cholesterol product include scheringplough net sale result sale reflect equity income addition virtual nature joint venture scheringplough incur substantial sell general administrative expense capture equity income include scheringploughs statement consolidated operation result scheringplough gross margin ratio sga expense expense percentage net sale reflect benefit impact joint venture operate result gross margin gross margin percent compare percent gross margin unfavorably impact million purchase accounting adjustment include cost sale purchase accounting adjustment result amortization fair value certain asset acquire obs acquisition gross margin compare benefit realize cost saving approximately million manufacturing streamline nonrecurrence million charge associate aforementioned manufacturing streamlining action favorable product mix despite negative impact cost sale cost result scheringplough action streamline manufacturing operation gross margin increase percent percent improvement gross margin primarily increase sale high margin product process improvement scheringploughs supply chain include cost saving manufacturing streamlining activity complete cost sale include charge total million associate scheringplough action streamline manufacturing operation offset saving approximately million result action note special acquisition relate charge manufacture streamline item financial statement supplemental datum additional information sell general administrative selling general administrative expense sga increase percent billion compare include sga million obs addition increase sga reflect high promotion spend ongoing investment emerge market unfavorable impact foreign exchange sga increase percent billion compare reflect ongoing investment emerge market field support product launch high promotional spending table content research development research development spending increase percent billion compare period include million ob include upfront payment million mainly relate certain licensing transaction increase spending versus reflect high spending clinical trial relate activity investment build great breadth capacity support continue expansion scheringplough pipeline spending increase percent billion compare period increase high cost associate clinical trial build great breadth capacity support scheringplough progress pipeline generally change spending reflect timing scheringplough fund internal research effort research collaboration partner discover develop steady flow innovative product maximize scheringplough chance successful development new product scheringplough begin development excellence initiative build talent critical mass create uniform level excellence deliver highpriority program scheringplough begin global clinical harmonization program maximize globalize quality clinical trial execution pharmacovigilance regulatory process certain aspect global clinical harmonization program implement acquire inprocess research development acquire inprocess research development charge billion result obs acquisition represent immediate expense recognition fair value acquire research project technological feasibility establish alternative future use incomeexpense net scheringplough income net million compare million income net expense net million income net include net realize gain foreign currency option million relate obs acquisition increase income net reflect high interest income high balance cash equivalent shortterm investment partially offset high interest expense issuance new debt special acquisition relate charge manufacture streamline special acquisition relate charge year end december scheringplough incur million special acquisitionrelate charge comprise million integrationrelate cost obs acquisition million severance charge integration activity manufacturing streamline scheringplough implement change manufacture operation puerto rico new jersey streamline global supply chain enhance scheringplough longterm competitiveness change result phaseout closure scheringplough manufacturing operation manati puerto rico additional workforce reduction las piedras puerto rico new jersey total action result elimination position scheringplough expect action yield annualize cost saving approximately million special charge special charge relate change scheringploughs manufacturing operation total million charge consist approximately million severance million fix asset impairment cost sale include cost sale approximately million consist million accelerate depreciation million inventory writeoff million charge relate closure scheringplough manufacturing facility manati puerto rico table content follow table summarize activity reflect consolidated financial statement relate change scheringploughs manufacturing operation complete charge include special total cash noncash accrue cost sale charge charge payment charge liability dollar millions accrue liability january severance asset impairment accelerate depreciation inventory writeoff total accrue liability december severance accrue liability december special charge activity special charge incur follow dollar million litigation charge employee termination cost asset impairment charge litigation charge litigation reserve increase million increase result total reserve million massachusetts investigation investigation state litigation disclose awp litigation investigation note legal environmental regulatory matter represent scheringplough current estimate resolve matter august scheringplough announce reach agreement attorney office district massachusetts department justice settle massachusetts investigation aggregate million plus interest settlement relate massachusetts investigation awp investigation litigation ongoing schering plough payment total million relate settlement employee termination cost employee termination cost consist million associate voluntary early retirement program verp million employee termination cost asset impairment charge year end december scheringplough recognize asset impairment charge million relate primarily consolidation scheringplough biotechnology organization equity income sale merckscheringplough cholesterol joint venture total billion billion billion respectively sale growth primarily high market share market growth continue expansion international market sale growth primarily increase market share table content company bear cost general sale force commercial overhead marketing joint venture product world canada puerto rico cholesterol agreement provide reimbursement company physician detail set annual basis italy contractual include profit sharing calculation reimburse canada puerto rico equal company physician detail multiply contractual fix fee scheringplough report amount equity income amount represent reimbursement specific incremental identifiable cost schere plough detail cholesterol product market addition amount reflective scheringplough sale effort relate joint venture scheringplough sale force relate cost associate joint venture generally estimate high cost joint venture company contractually share portion manufacturing cost specifically identify promotion cost include directtoconsumer advertising direct identifiable outofpocket promotion agree cost specific service market support market research market expansion specialty sale force physician education program certain specify research development expense generally share equally scheringplough merck certain condition specify joint venture agreement merck scheringplough entitle receive reimbursement future research development expense million additional information joint venture merck include note equity income item financial statement supplementary data equity income merckscheringplough joint venture total billion billion million respectively increase equity income compare reflect high market share international sale growth increase equity income compare reflect continue strong sale vytorin zetia scheringplough recognize milestone merck million relate certain european approval vytorin ezetimibesimvastatin note scheringplough incur substantial sell general administrative cost reflect equity income instead include overall cost structure scheringplough provision income taxis tax expense million million million respectively tax provision include tax benefit million relate amortization fair value certain asset acquire obs acquisition income tax provision primarily relate foreign taxis tax provision include benefit million related irs notice issue august result reduction previously accrue tax liability attributable repatriation american job creation act ajca tax provision include benefit relate operating loss schere plough establish valuation allowance net defer tax asset include benefit operating loss management conclude likely benefit net defer tax asset realize december schering plough continue maintain valuation allowance net defer tax asset scheringplough expect report net operating loss nol carryforward billion tax return year end december nol carryforward materially reduce examination scheringplough income tax return internal revenue service irs scheringplough generate approximately million loss include impact purchase accounting difference financial tax reporting scheringplough expect report minimal increase nol tax return scheringplough implement provision fasb interpretation accounting uncertainty income taxis fin january require fin cumulative effect apply provision interpretation report adjustment scheringplough retain earning table content balance january scheringplough reduced january retain earning million result adoption fin scheringploughs unrecognized tax benefit result primarily vary application statute regulation interpretation include exposure intercompany term cross border arrangement utilization cash hold foreign subsidiary investment property scheringplough tax matter litigation note legal environmental regulatory matter item financial statement supplemental datum additional information january december total unrecognized tax benefit million million respectively include reduction defer tax asset carry valuation allowance potential refund claim tax liability january december approximately million million respectively total unrecognized tax benefit recognize affect effective tax rate management believe reasonably possible total unrecognized tax benefit decrease twelvemonth period million decrease primarily attributable decision tax matter currently litigate newark district court possible final resolution scheringplough examination irs appeal possible resolution matter time ultimate resolution scheringplough tax matter payment andor receipt relate cash dependent number factor outside scheringploughs control scheringplough include interest expense income potential penalty relate tax position component income tax expense statement consolidated operation total accrue interest relate tax position january december million million respectively include accrue liability second quarter irs complete examination scheringplough federal income tax return schere plough seek resolution issue raise examination irs administrative appeal process scheringplough remain open irs tax year significant tax jurisdiction state foreign scheringploughs income tax return open examination period net lossincome available common shareholder scheringplough net lossincome available common shareholder billion billion million respectively net loss available common shareholder include approximately billion charge relate purchase accounting obs acquisition include billion acquire inprocess research development charge net loss available common shareholder include deduction prefer stock dividend million relate preferred stock net income available common shareholder include deduction prefer stock dividend million period relate preferred stock net lossincome available common shareholder include special acquisition relate charge manufacture streamlining cost approximately million million million respectively note special acquisition relate charge manufacture streamline item financial statement supplementary datum additional information liquidity financial resource discussion cash flow ar end december dollar million cash flow operating activity cash flow investing activity cash flow financing activity table content operating activity operating activity provide billion cash compare net cash provide operation billion increase primarily net realize gain million foreign currency option relate obs acquisition high net sale equity income partially offset payment million settlement massachusetts investigation million tax interest connection examination irs scheringploughs federal income tax return overall risk management strategy consideration preliminary financing scenario associate acquisition obs scheringplough purchase eurodenominate currency option derivative aggregate premium approximately million receive proceed million termination option result net realize gain million derivative shortterm trading nature hedge specific financing investment transaction accordingly cash impact derivative classified operating cash flow statement consolidated cash flow net cash provide operating activity billion increase billion compare increase primarily result high net income timing operate cash payment receipt operating activity generate million cash include payment approximately million tax authority tax liability relate repatriation foreign earning ajca tax payment million relate settlement certain tax contingency tax year invest activity net cash investing activity billion primarily consist billion net cash purchase obs addition source cash investing activity include net reduction shortterm investment billion partially offset million capital expenditure net cash investing activity billion primarily relate net purchase shortterm investment billion previously invest cash equivalent million capital expenditure net cash investing activity million primarily relate million capital expenditure purchase intangible asset million partially offset proceed sale property equipment million net reduction shortterm investment million financing activity net cash provide financing activity billion compare cash billion period net cash provide financing activity include net proceed issuance common mandatory convertible preferred share approximately billion billion respectively net proceed approximately billion issuance longterm debt net cash provide financing activity include million proceed stock option exercise offset payment dividend common prefer share million net cash financing activity billion million respectively use cash financing activity include payment dividend common prefer share million million respectively repayment billion bank debt shortterm commercial paper borrowing billion shortterm commercial paper borrowing use cash financing activity partially offset proceed million bank debt incur foreign subsidiary relate funding portion repatriation ajca bank debt fully repay table content discussion cash flow scheringplough move forward additional investment enhance infrastructure business currently process build pharmaceutical sciences center new jersey capital expenditure approximately million million respectively relate center additional capital expenditure approximately million expect year center allow scheringplough streamline integrate drug development process product move drug discovery pipeline market additional related expenditure upgrade equipment staffing center december scheringplough net debt total debt cash cash equivalent shortterm investment marketable security billion cash generate operation available cash shortterm investment available credit facility expect provide scheringplough ability fund cash need intermediate term borrowing credit facility september scheringplough issue billion aggregate principal percent senior unsecured note billion aggregate principal percent senior unsecured note net proceed offer approximately billion interest note payable semiannually effective interest rate percent senior unsecured note percent senior unsecured note incorporate initial discount debt issuance fee percent percent respectively interest rate payable note subject adjustment note generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidate net tangible asset note redeemable scheringplough option time redemption price equal great percent principal note sum present value remain schedule payment principal interest discount redemption date semiannual basis rate treasury note comparable remain term plus basis point note basis point note change control trigger event occur define prospectus holder note right require scheringplough repurchase note cash payment equal percent aggregate principal note repurchase plus accrue unpaid interest date purchase october scheringplough issue euro million aggregate principal percent senior unsecured euro denominate note euro billion aggregate principal percent senior unsecured eurodenominate note net proceed offer approximately billion interest note payable annually effective interest rate percent senior unsecured eurodenominate note percent senior unsecured eurodenominate note incorporate initial discount debt issuance fee impact interest rate hedge percent percent respectively interest rate payable note subject adjustment note generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidate net tangible asset note redeemable scheringplough option time redemption price specify prospectus change control trigger event occur define prospectus holder note right require scheringplough repurchase note cash payment equal percent aggregate principal note repurchase plus accrue unpaid interest date purchase scheringplough net proceed note fund portion purchase price obs acquisition october scheringplough enter fiveyear senior unsecured eurodenominate term loan facility syndicate bank october scheringplough draw euro billion billion term loan fund portion purchase price obs acquisition new term table content loan float interest rate require scheringplough maintain net debt total capital ratio percent percent net debt equal total debt cash cash equivalent shortterm investment marketable security total capital equal sum total debt total shareholder equity exclude cumulative effect acquire inprocess research development connection acquisition consummate closing term loan term loan generally restrict schere plough create assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidate net tangible asset report dollar amount outstanding debt balance interest expense eurodenominate note euro denominate term loan fluctuate impact foreign currency translation november scheringplough issue billion aggregate principal percent senior unsecured note billion aggregate principal percent senior unsecured note interest rate payable note subject adjustment connection rating downgrade december interest rate payable note increase percent percent interest rate payable note increase percent percent interest rate payable particular series note return percent percent respectively rate adjustment provision permanently cease apply note subsequently rate baa moodys bbb rating assign note moodys downgrade respectively interest rate payable series note increase note borrowing commitment item financial statement supplementary datum additional information august scheringplough enter billion revolving credit agreement syndicate bank terminate billion credit facility mature credit facility float interest rate mature august require scheringplough maintain net debt total capital ratio percent percent net debt equal total debt cash cash equivalent shortterm investment marketable security total capital equal sum total debt total shareholder equity exclude cumulative effect acquire inprocess research development connection acquisition consummate closing credit facility credit facility generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidate net tangible asset credit line available general corporate purpose consider support scheringplough commercial paper borrowing borrowing credit facility draw parent company whollyowne international subsidiary accompany parent guarantee facility require compensating balance nominal commitment fee pay december borrowing outstanding facility december shortterm borrowing include credit facility mention total million million respectively include outstanding commercial paper million date weightedaverage interest rate short term borrowing december percent percent respectively scheringplough senior unsecured eurodenominate note eurodenominate term loan designate effective economic hedge net investment foreign operation accordance sfas foreign currency translation sfas foreign currency transaction gain loss eurodenominate debt instrument include foreign currency translation adjustment comprehensive income table content credit rating scheringplough current unsecured senior credit rating outlook follow longterm senior unsecured credit rating longterm shortterm review status moodys investor service baa stable standard poor stable fitch rating bbb stable shortterm rating discuss significantly affect scheringplough ability issue rollover outstanding commercial paper borrowing time scheringplough believe ability commercial paper issuer scheringplough shortterm credit rating moodys andor fitch issue rollover outstanding commercial paper time company high shortterm credit rating addition total commercial paper capacity available issuer typically higherrate company scheringplough sizable line credit commercial bank cash shortterm investment hold international subsidiary serve alternative source liquidity support commercial paper program scheringplough credit rating decline current level impact decline reduce availability commercial paper borrowing increase interest rate portion scheringplough short longterm debt discuss scheringplough believe exist cash shortterm investment available credit facility cash generate operation allow scheringplough fund cash need intermediate term mandatory convertible preferred stock august scheringplough issue share percent mandatory convertible preferred stock prefer stock face value billion net proceed scheringplough approximately billion deducting commission discount underwriting expense scheringplough net proceed sale prefer stock fund portion purchase price obs acquisition share prefer stock automatically convert common share scheringplough depend average closing price scheringplough common share trading day period end trading day prior mandatory conversion date august define prospectus prefer shareholder elect convert time prior august minimum conversion ratio common share share prefer stock additionally time prior mandatory conversion date closing price scheringplough common share exceed trading day period consecutive trading day scheringplough elect cause conversion prefer stock outstanding minimum conversion ratio common share share preferred stock prefer stock accrue dividend annual rate percent share outstanding dividend cumulative date issuance extent scheringplough legally permit pay dividend board director declare dividend payable scheringplough pay dividend dividend payment date dividend payment date february august november year dividend pay november year end december share percent mandatory convertible preferred stock issue august preferred stock convert share scheringplough common stock table content equity issuance treasury share august scheringplough issue common share treasury share share net proceed scheringplough approximately billion deducting commission discount underwriting expense scheringplough net proceed sale common share fund portion purchase price obs acquisition note acquisition item financial statement supplementary datum contractual obligation offbalance sheet arrangement scheringplough contractual obligation report liability consolidated balance sheet require recognize liability certain purchase commitment executory contract follow table summarize payment period scheringplough know contractual obligation december ment period total year year year year dollar million shortterm borrowing current portion longterm debt longterm debt obligation operating lease obligation purchase obligation defer compensation plan obligation obligation total longterm debt obligation include aggregate principal longterm debt exclude interest obligation note borrowing commitment item financial statement supplementary datum additional information purchase obligation include advertising research contract capital expenditure commitment inventory expense item material research milestone payment likely pay include potential milestone payment payment contingent occurrence certain event table exclude research contract cancelable scheringplough penalty purchase obligation consist cancelable noncancelable item caption include obligation base undiscounted amount estimate payment certain scheringplough pension plan prefer stock dividend management estimate current portion unrecognize tax benefit contractual obligation regulatory competitive environment scheringplough operate scheringplough subject jurisdiction national state local regulatory agency regulation describe detail item business regulatory compliance complex regulatory standard include good clinical practice good laboratory practice good manufacturing practice vary jurisdiction constantly evolve regulatory compliance costly regulatory compliance impact timing need bring new drug market market drug new indication failure comply regulation result delay approval drug seizure recall drug suspension revocation authority necessary production sale drug fine civil criminal sanction table content regulatory compliance cost compliance failure material impact scheringplough result operation cash flow financial condition unknown science human health drug benefit risk societal government pressure constantly shift demand innovation meet urgent unmet medical need adversity risk pressure impact regulatory environment market scheringplough product regulatory compliance pharmacovigilance consent decree august scheringplough announce dissolution consent decree district court district new jersey note consent decree item financial statement regulatory inspection scheringplough subject pharmacovigilance reporting requirement country jurisdiction include member states requirement differ jurisdiction jurisdiction include requirement report adverse event occur patient particular drug order alert drug manufacturer governmental agency potential problem pharmacovigilance inspection official british french medicine agency conduct request european medicine agency emea cite deficiency report process scheringplough continue work long term action plan rectify deficiency provide regular update emea fourth quarter local emea regulatory authority conduct follow inspection assess scheringplough implementation action plan quarter authority inspect usbased component scheringplough pharmacovigilance system inspector acknowledge progress continue note significant concern quality system support scheringploughs pharmacovigilance process similarly follow inspection schering plough clinical trial practice inspector identify issue respect scheringploughs management clinical trial relate pharmacovigilance practice february scheringplough begin global clinical harmonization program building clinical excellence trial design execution tracking strengthen scheringploughs scientific compliance rigor global basis certain aspect global clinical harmonization program implement work expect continue year addition fourth quarter local regulatory authority conduct followup inspection confirm corrective action commit scheringplough follow inspection scheringplough ukbase clinical trial operation fact complete early january local regulatory authority return followup inspection scheringplough pharmacovigilance operation inspection likewise confirm number corrective action complete inspection note number action scheringplough taken set forth scheringplough periodic update emea note limited number observation scheringplough address scheringplough intend continue upgrade skill process system clinical practice pharmacovigilance scheringplough remain committed accomplish work invest significant resource area scheringplough know action emea national authority response inspection possible action include inspection demand improvement report system criminal sanction schere plough andor responsible individual change condition marketing authorization scheringplough product table content regulatory compliance postmarkete surveillance scheringplough engage clinical trial research country world clinical trial research activity comply stringent regulatory standard subject inspection local country regulatory authority failure comply current good clinical practice applicable law regulation result delay approval clinical trial suspension ongoing clinical trial delay approval marketing authorization criminal sanction scheringplough andor responsible individual change condition marketing authorization scheringplough product clinical trial postmarkete surveillance certain market drug competitor industry raise safety concern lead recall withdrawal adverse labeling market product addition situation raise concern prescriber patient relate safety efficacy pharmaceutical product general past year occurrence increase recently medium mischaracterization early topline result enhance clinical trail lead concern patient prescriber zetia vytorin discussion early development executive summary management discussion analysis financial condition result operation scheringplough personnel regular open dialogue fda regulator review product label material regular basis new information know follow wave recent product withdrawal company significant safety issue health authority fda emea pmda continue increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication review select product market add uncertainty regulatory process great regulatory scrutiny especially advertising promotion particular directtoconsumer advertising similarly major health authority include fda emea pmda increase collaboration especially regard evaluation safety benefitrisk information medium attention increase current environment health authority regulatory action market safety labeling change regulatory prescribing marketing implication market extent previously see health authority pmda japan publicly acknowledge significant backlog workload resource constraint agency backlog cause long regulatory review time new indication product add uncertainty predict approval timeline market pmda committed correct backlog progress year expect continue foreseeable future uncertainty inherent government regulatory approval process include thing delays approval new product formulation indication affect scheringplough operation effect regulatory approval process operation predict scheringplough achieve significant number important regulatory approval include approval vytorin noxafil clarinex clarinex reditab clarinex suboxone new indication temodar nasonex significant approval include asmanex dpi dry powder inhalation pegintron zetia temodar esmeroneslax japan new indication remicade scheringplough number significant regulatory submission file major market await approval pricing pressure describe specifically note legal environmental regulatory matter item financial statement price sale marketing program arrangement relate business table content practice scheringplough participant health care industry increase scrutiny federal state regulatory investigative prosecutorial administrative entity entity include department justice attorney office office inspector general department health human service fda federal trade commission ftc state attorney general office health care law certain governmental entity operate include federal state antikickback statute statutory common law false claim law construe broadly court permit government entity exercise significant discretion event governmental entity believe wrongdoing occur institute civil criminal proceeding institute resolve unfavorably subject scheringplough substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program scheringplough predict investigation affect marketing practice sale result material adverse impact scheringplough result operation cash flow financial condition business scheringploughs pharmaceutical product subject increasingly competitive pricing manage care group institution government agency group seek price discount market scheringplough pharmaceutical manufacturer require provide statutorily define rebate government agency order participate medicaid veterans health care program governmentfunde program medicare prescription drug improvement modernization act contain prescription drug benefit individual eligible medicare prescription drug benefit effective january result increase use generic increase purchasing power negotiating behalf medicare recipient international market scheringplough operate environment government mandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug enact acrosstheboard price cut method control cost scheringplough unable predict final form time future domestic international governmental health care initiative include passage law permit importation pharmaceutical effect operation cash flow reasonably estimate similarly effect operation cash flow decision government entity manage care group group concern formulary pharmaceutical reimbursement policy reasonably estimate competition market pharmaceutical product competitive scheringplough operation affect technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor new information clinical trial market product postmarkete surveillance generic competition scheringplough product mature addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product effect operation competitive factor patent dispute predict outlook scheringplough provide numeric guidance follow outlook helpful reader assess future prospect early discussion matter relate merckscheringplough cholesterol joint venture enhance clinical trial im prescription datum show date prescription vytorin zetia decline prescription datum show early sign stabilization limitation prescription datum early discern trend datum likely weekly fluctuation ims report prescription volume vytorin zetia table content trend identify wholesaler retail chain trade buyer respond fluctuation change buy pattern reduce inventory level early determine business financial impact low prescription volume longerterm quarter merckscheringplough cholesterol joint venture sale vytorin zetia likely negatively impact scheringplough account joint venture equity method scheringplough successful advance research development project late stage project require sizable resource complete research development expense expect continue increase year result expand pipeline pipeline project add obs acquisition need large frequent long clinical trial current global regulatory environment risk describe item risk factor cause actual result differ materially expectation provide section impact recently issue accounting standard september fasb issue sfas fair value measurement standard define fair value establishe framework measure fair value accordance generally accept accounting principle expand disclosure fair value measurement standard codifie definition fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date standard clarifie principle fair value base assumption market participant use price asset liability establish fair value hierarchy prioritize information develop assumption calendar year company standard effective beginning january nonfinancial item measure nonrecurre basis effective begin january base scheringploughs current financial position impact standard consolidated financial statement expect material november fasb issue emerge issue task force issue eitf account defer compensation postretirement benefit aspect collateral assignment splitdollar life insurance arrangement effective calendar year company january task force conclude employer recognize liability postretirement benefit relate collateral assignment splitdollar life insurance arrangement accordance fasb statement apb opinion base substantive agreement employee task force conclude employer recognize measure asset base nature substance collateral assignment splitdollar life insurance arrangement impact standard consolidated financial statement expect material february fasb issue sfas fair value option financial asset financial liabilitiesincluding amendment fasb statement sfas permit entity choose measure financial instrument certain item fair value sfas include amendment sfas account certain investment debt equity security apply entity availableforsale trading security statement effective begin entity fiscal year begin november base scheringploughs current financial position impact standard consolidated financial statement expect material june fasb issue eitf issue account nonrefundable advance payment good service receive use future research development activity effective calendar year company january task force conclude nonrefundable advance payment good service render future research development activity defer capitalize amount recognize expense relate good table content deliver service perform good service long expect provide impact standard consolidated financial statement expect material december fasb issue eitf issue accounting collaborative arrangement effective calendar year company january task force clarify manner cost revenue share payment receive partner collaborative arrangement present income statement set forth certain disclosure require partner financial statement scheringplough currently assess potential impact implement standard december securities exchange commission sec issue staff accounting bulletin sab permit entity certain circumstance continue use simplified method estimate expect term plain vanilla option discuss sab accordance sfas revise sharebased payment guidance release effective january impact standard consolidated financial statement expect material december fasb issue sfas revise business combination calendar year company standard applicable new business combination occur january sfas require acquire entity recognize asset acquire liability assume transaction acquisitiondate fair value limit exception significantly sfas require acquisition cost generally expense incur certain acquire contingent liability record fair value acquire inprocess research development record fair value indefinitelive intangible asset acquisition date standard impact certain unresolved matter relate purchase transaction consummate prior effective date standard scheringplough currently assess potential impact implement standard december fasb issue sfas noncontrolle interest consolidate financial statement amendment arb effective fiscal year interim period fiscal year begin december standard establish new accounting reporting standard noncontrolle interest subsidiary deconsolidation subsidiary scheringplough currently assess potential impact implement standard critical accounting policy estimate follow accounting policy estimate consider significant change certain judgment assumption inherent policy affect scheringplough financial statement revenue recognition rebate discount return provision income taxis acquisition impairment goodwill intangible asset property accounting pension postretirement benefit plan account legal regulatory matter revenue recognition scheringploughs pharmaceutical product sell direct purchaser include wholesaler retailer certain health maintenance organization price discount rebate sale pay federal state agency indirect purchaser market participant manage care organization indemnify beneficiary health plan pharmaceutical cost pharmacy benefit manager table content scheringplough recognize revenue title risk loss pass purchaser reliable estimate follow determined commercial discount rebate arrangements rebate obligation certain federal state governmental program iii sale return normal course business recognize revenue scheringplough estimate record applicable commercial governmental discount rebate sale return expect grant product sell period amount deduct sale period reliable estimate item scheringplough defer recognition revenue estimate record prior period reevaluate process revenue recognition new product base specific fact circumstance include estimate acceptance rate establish product similar marketing characteristic absent ability reliable estimate rebate discount return scheringplough defer revenue recognition product discount grant base term arrangement wholesaler managedcare organization government purchaser certain market condition rebate estimate base sale contract term historical experience trend analysis project market condition market serve scheringplough evaluate market condition product group product primarily analysis party demand market research datum internally generate information datum information provide purchaser obtain party subject inherent limitation accuracy validity sale return estimate record base historical sale return information analysis recent wholesale purchase information consideration stocking level wholesaler forecast demand amount product exhibit unusual sale return pattern dating competition include expect generic introduction marketing matter specifically investigate analyze formulation return reserve scheringplough agreement major pharmaceutical wholesaler address number commercial issue product return time payment processing chargeback quantity inventory hold wholesaler respect quantity inventory hold wholesaler agreement provide financial disincentive wholesaler acquire quantity product excess necessary meet current patient demand use agreement scheringplough expect avoid situation scheringplough shipment product reflective current demand rebate discount return scheringploughs rebate accrual federal state governmental program include medicaid medicare december million million respectively commercial discount return rebate accrual december million million respectively accrual establish period relate revenue recognize result reduction sale establishment liability include total current liability case return receivable adjustment allowance provide account receivable case governmental rebate programs scheringploughs payment involve interpretation relevant statute regulation interpretation subject challenge change interpretive guidance governmental authority result challenge change affect estimate governmental rebate amount ultimately sufficient satisfy schere plough obligation additional information governmental inquiry focus calculation rebate contain note legal environmental regulatory matter item financial statement supplementary datum addition possible result governmental challenge change interpretive guidance actual rebate materially exceed amount accrue table content follow summarize activity account relate accrued rebate sale return discount ear end ear end december december dollar millions accrue rebatesreturnsdiscount begin period ob accrual acquire november provision rebate adjustment prioryear estimate payment provision return adjustment prioryear estimate return provision discount adjustment prioryear estimate discount grant accrue rebatesreturnsdiscount end period year end december adjustment prioryear estimate rebate include million relate reversal previously accrue rebate amount record government tricare retail pharmacy program federal court rule pharmaceutical manufacturer obligate pay formulate recording accrual management utilize assumption estimate include historical experience wholesaler datum projection market condition estimate lag time sale payment rebate utilization estimate forecast product demand amount discuss critical accounting policy entitle revenue recognition review accrual management perform sensitivity analysis consider differ assumption subject judgment rebate accrual calculation base scheringplough sensitivity analysis reasonably possible change assumption relate rebate accrual favorably unfavorably impact net sale income taxis consistent provision income taxis scheringplough implement provision fasb interpretation accounting uncertainty income taxis fin january require fin cumulative effect apply provision interpretation report adjustment scheringplough retain earning balance january scheringplough reduced january retain earning million result adoption fin scheringploughs unrecognized tax benefit result primarily vary application statute regulation interpretation include exposure intercompany term cross border arrangement utilization cash hold foreign subsidiary investment property scheringplough tax matter litigation note legal environmental regulatory matter january december total unrecognized tax benefit million million respectively include reduction defer tax asset carry valuation allowance potential refund claim tax liability january december approximately million million respectively total unrecognized tax benefit recognize affect effective tax rate management believe reasonably possible total unrecognized tax benefit decrease table content twelvemonth period million decrease primarily attributable decision tax matter currently litigate newark district court possible final resolution taxpayer examination irs appeal possible resolution matter time ultimate resolution scheringplough tax matter payment andor receipt relate cash dependent number factor outside scheringploughs control scheringplough include interest expense income potential penalty uncertain tax position component income tax expense statement consolidated operation total accrue interest relate uncertain tax position january december million million respectively include accrue liability scheringplough record valuation allowance reduce defer tax asset likely realize scheringplough consider ongoing prudent feasible tax planning strategy assess need valuation allowance event scheringplough determine able realize additional portion net defer tax asset adjustment valuation allowance increase income period determination likewise scheringplough subsequently determine able realize additional portion remain net defer tax asset future adjustment defer tax asset charge income period determination acquisition impairment goodwill intangible asset property scheringplough account acquire business purchase method accounting require asset acquire liability assume record date acquisition respective fair value consolidate financial statement result operation reflect acquire business completion acquisition cost acquire business include transaction cost allocate underlie net asset acquire business base respective fair value excess purchase price estimate fair value net asset acquire record goodwill amount allocate acquire inprocess research development expense date acquisition intangible asset amortize base sale expect life asset judgment determine estimate fair value assign class asset acquire liability assume asset live materially impact result operation useful life determine base expect future period benefit asset consider characteristic asset include project cash flow intangible asset represent capitalize cost purchase goodwill patent license form intellectual property total billion december intangible asset goodwill increase significantly acquisition obs annual amortization expense year estimate approximately million year base intangible asset record december value asset subject continue scientific medical marketplace uncertainty example market pharmaceutical product withdraw market safety reason marketing product occur pronounce warning amount capitalize product need reduce impairment event give rise impairment inherent risk pharmaceutical industry predict management regularly review intangible asset possible impairment certain scheringplough manufacturing site operate capacity overall cost operate manufacturing site significantly increase consent decree compliance activity scheringplough manufacturing cost base relatively fix action management significantly reduce scheringploughs manufacturing infrastructure involve complex issue result shift product manufacturing plant year construction regulatory requirement include revalidation registration requirement management continue review carry value certain manufacturing asset indication impairment future event decision lead additional asset impairment andor relate cost table content accounting pension postretirement benefit plan pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption scheringplough assess pension postretirement benefit plan assumption regular basis evaluate assumption scheringplough consider factor include evaluation discount rate expect rate return plan asset healthcare cost trend rate retirement age assumption scheringplough historical assumption compare actual result analysis current market condition asset allocation note retirement plan postretirement benefit item financial statement supplementary datum additional information discount rate pension postretirement benefit plan calculation evaluate annually modify reflect prevail market rate measurement date highquality fix income debt instrument portfolio provide future cash flow need pay benefit include benefit obligation come country debt instrument thinly trade estimate base available market rate actuarial assumption base management good estimate judgment assumption hold constant increase basis point discount rate estimate favorable impact million net pension postretirement benefit cost increase basis point expect rate return assumption estimate favorable impact million net pension postretirement benefit cost assumption hold constant decrease basis point discount rate estimate unfavorable impact million net pension postretirement benefit cost decrease basis point expect rate return assumption estimate unfavorable impact million net pension postretirement benefit cost sensitivity base estimate net pension postretirement benefit cost include annual impact ob plan expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return scheringplough determine expect return major asset class principally equities fix income real estate return expectation asset class base assumption economic growth inflation support longterm historical datum scheringplough actual experience return plan asset expect portfolio performance reflect contribution active management appropriate unrecognized net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption expect return base primarily calculate marketrelated value asset methodology asset gainslosse result actual return differ scheringplough expect return majority asset realize marketrelated value asset ratably fiveyear period total unrecognized net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee target investment portfolio scheringplough retirement plan allocate percent equity percent fix income investment percent real estate target investment portfolio scheringplough postretirement benefit plan allocate percent equity percent fix income investment portfolio equity weighting consistent longterm nature plan benefit obligation nonus pension plan target investment portfolio vary base duration pension liability local governmental rule regulation substantially investment equities fix income value base quote public market value investment real estate value base periodic appraisal september fasb issue sfas employer account define benefit pension postretirement plan amendment fasb statement effective december scheringplough account retirement postretirement benefit plan accordance sfas shareholder equity december reduce table content approximately percent adoption sfas note retirement plan postretirement benefit item financial statement supplemental datum additional information sfas allow extended adoption date requirement scheringploughs yearend date measurement date define benefit pension postretirement plan plan measurement date yearend prior adoption sfas scheringplough adopt yearend measurement date effective impact consolidate financial statement relate measurement date change material account legal regulatory matter management judgment estimate require account legal regulatory matter ongoing basis include insurance coverage scheringplough review status claim investigation legal proceeding ongoing basis time time scheringplough settle resolve matter term condition management believe good interest scheringplough resolution claim investigation legal proceeding individually aggregate material adverse effect scheringplough result operation cash flow financial condition market risk disclosure scheringplough expose market risk primarily change foreign currency exchange rate less extent interest rate equity price follow describe nature risk foreign currency exchange risk scheringplough subsidiary country sale outside account approximately percent global sale virtually sale denominate currency local country scheringplough report profit cash flow expose change exchange rate date management deem cost effective engage formulabase program hedge profit cash flow international operation derivative financial instrument scheringplough international subsidiary purchase significant quantity inventory payable dollar manage level inventory relate payable rate inventory turnover provide level protection adverse change exchange rate risk adverse exchange rate change mitigate fact scheringplough international operation widespread addition point time scheringplough international subsidiary hold financial asset liability denominate currency dollar financial asset liability consist primarily shortterm thirdparty intercompany receivables payable change exchange rate affect translate value financial asset liability gain loss arise translation affect net income occasion scheringplough derivative hedge specific foreign currency exposure overall risk management strategy consideration preliminary financing scenario associate acquisition obs scheringplough purchase eurodenominate currency option mitigate exposure event significant strengthening euro compare dollar scheringplough purchase option aggregate premium approximately million receive proceed million termination option result net realize gain million derivative qualify hedge accounting accordance sfas accounting derivative instrument hedge activity amend sfas accordingly gain derivative recognize statement consolidated operation december open foreign currency option contract scheringplough senior unsecured eurodenominate note eurodenominate term loan designate effective economic hedge net investment foreign operation accordance sfas foreign currency transaction gain loss eurodenominate debt instrument include foreign currency translation adjustment comprehensive income table content interest rate equity price risk financial asset expose change interest rate andor equity price primarily cash equivalent shortterm investment debt equity security hold qualified nonqualified trust employee benefit asset total billion december cash equivalent shortterm investment percent decrease interest rate decrease interest income approximately million security hold qualified nonqualified trust longterm nature liability trust asset fund scheringplough exposure market risk deem low financial obligation expose variability interest rate primarily shortterm borrowing longterm floatingrate euro denominate term loan scheringplough longterm fix rate debt outstanding percent decrease interest rate increase fair value debt approximately million scheringplough execute series interest rate swap anticipation financing acquisition obs objective swap hedge interest rate payment future issuance debt swap designate cash flow hedge future interest payment accordance sfas effective portion gain loss hedge report comprehensive income ineffective portion report operation connection eurodenominate debt issuance describe note borrowing commitment item financial statement supplementary datum portion swap deem ineffective scheringplough recognize million loss statement consolidated operation effective portion swap million record comprehensive income recognize interest expense life relate debt december open interest rate swap disclosure notice cautionary statement private security litigation reform act management discussion analysis financial condition result operation section report write report oral statement time time scheringplough contain forwardlooke statement mean private security litigation reform act forwardlooke statement relate strictly historical current fact base current expectation forecast future event identify forwardlooke statement use word anticipate believe estimate expect forecast project intend plan potential similar word term particular forwardlooke statement include statement relate future action ability access capital market pende acquisition prospective product product approval time condition regulatory approval patent intellectual property protection future performance effectiveness market product pipeline drug trend performance include trend cholesterol market sale effort research development program anticipate spending estimate rebate discount return expense program reduce expense outcome contingency litigation investigation growth strategy expect synergies financial result forwardlooke statement publication turn wrong guarantee schere plough financial operational performance performance scheringplough stock scheringplough assume obligation update forwardlooke statement factor cause actual result differ scheringplough forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know possible predict identify factor scheringplough refer item risk factor report incorporate reference identification important factor respect risk uncertainty item quantitative qualitative disclosure market risk market risk disclosure set forth item management discussion analysis financial condition result operation item financial statement supplementary datum index financial statement statement consolidated operation year end december statement consolidated cash flow year end december consolidated balance sheet december statement consolidated shareholder equity year end december note consolidated financial statement report independent register public accounting firm table content scheringplough corporation subsidiary statement consolidated operation amount million share figure ears december net sale cost sale sell general administrative research development acquire inprocess research development incomeexpense net special acquisitionrelate charge equity income lossincome income taxis income tax expense net lossincome cumulative effect change accounting principle cumulative effect change accounting principle net tax net lossincome prefer stock dividend net lossincome available common shareholder dilute lossearning common share lossearning available common shareholder cumulative effect change accounting principle cumulative effect change accounting principle net tax dilute lossearning common share basic lossearning common share lossearning available common shareholder cumulative effect change accounting principle cumulative effect change accounting principle basic lossearning common share dividend common share accompany note integral consolidated financial statement table content scheringplough corporation subsidiary statement consolidated cash flow amount million ear ded december operating activity net lossincome cumulative effect change accounting principle net tax net lossincome cumulative effect change accounting principle net tax adjustment reconcile net lossincome cumulative effect change accounting principle net tax net cash provide operating activity depreciation amortization accrue sharebase compensation special acquisition relate charge payment purchase derivative currency option change fair value currency option proceed derivative instrument acquire inprocess research development payment tax authority change asset liability account receivable inventory prepaid expense asset account payable liability income taxis payable foreign currency transaction exchange loss net net cash provide operating activity invest activity capital expenditure dispositions property equipment acquisition net cash acquire purchase shortterm investment maturitie shortterm investment net net cash investing activity financing activity cash dividend pay common shareholder cash dividend pay prefer shareholder proceed prefer stock issuance net proceed common stock issuance net issuance longterm debt net shortterm borrowing payment shortterm borrowing stock option exercise net net cash provide byused financing activity effect exchange rate cash cash equivalent net decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year supplemental disclosure cash pay interest net amount capitalize cash pay income taxis note accompany note integral consolidated financial statement table content scheringplough corporation subsidiary consolidate balance sheet amount million share figure mber assets current asset cash cash equivalent shortterm investment account receivable allowance inventory defer income taxis prepaid expense current asset total current asset property cost land building improvement equipment construction progress total accumulate depreciation property net goodwill intangible asset net asset total asset liability shareholder equity current liability account payable shortterm borrowing current portion longterm debt income taxis accrue compensation accrue liability total current liability longterm liability longterm debt net current portion defer income taxis longterm liability total longterm liability commitment contingent liability note shareholder equity mandatory convertible preferred share par value share face value issue december december mandatory convertible preferred share par value share face value issue december december common share authorize share par value issue december december paidin capital retain earning accumulate comprehensive loss total treasury share cost total shareholder equity total liability shareholder equity accompany note integral consolidated financial statement table content scheringplough corporation subsidiary statement consolidated shareholder equity amount million cumulate mandatory mandatory total convertible convertible compre share prefer preferred common paidin retain treasury hensive holder share share share capital earning share loss equity balance january comprehensive incomeloss net income foreign currency translation minimum pension liability net tax sfas total comprehensive income cash dividend common share dividend preferred share stock incentive plan balance december comprehensive income net income foreign currency translation minimum pension liability net tax sfas unrealize gain investment available sale net tax total comprehensive income cash dividend common share dividend preferred share accrue dividend common share adjustment pension otherpostretirement liability adoption sfas net tax stock incentive plan balance december adoption fin comprehensive lossincome net loss foreign currency translation pension otherpostretirement liability net tax derivative interest rate instrument unrealize gain investment available sale net tax total comprehensive loss issuance preferred stock issuance common stock conversion prefer stock sfas measurement date provision net tax cash dividend common share dividend preferred share accrue dividend common share stock incentive plan balance december accompanying note integral consolidated financial statement table content note consolidated financial statement summary significant accounting policy overview scheringplough innovationdriven sciencecentere global health care company biopharmaceutical research collaboration partner scheringplough create therapy help save improve life world scheringplough apply researchanddevelopment platform human prescription consumer product animal health product november scheringplough acquire organon bioscience obs company discover develop manufacture human prescription animal health product note acquisition additional information principle consolidation consolidated financial statement include scheringplough corporation subsidiary scheringplough intercompany balance transaction eliminate account obs include scheringplough result date acquisition november use estimate preparation financial statement conformity accounting principle generally accept require management estimate assumption affect report amount asset liability disclosure contingent asset liability date financial statement report amount revenue expense report period ongoing basis scheringplough evaluate estimate base historical experience assumption believe reasonable circumstance actual result differ estimate equity method accounting scheringplough account share activity merckscheringplough joint venture joint venture merck inc merck equity method accounting scheringplough significant influence joint venture operate financial policy accordingly scheringplough net sale include sale joint venture scheringplough share earning joint venture include equity income determine consolidated net incomeloss equity income joint venture include human prescription pharmaceutical segment revenue sale vytorin zetia recognize joint venture title risk loss pass customer equity income joint venture exclude profit arise transaction scheringplough joint venture time underlying profit realize joint venture transaction party scheringplough merck note equity income additional information joint venture cash cash equivalent cash cash equivalent include operate cash highly liquid investment original maturity month include highlyrate money market account shortterm investment shortterm investment carry fair value classify availableforsale investment consist certificate deposit commercial paper maturity year table content note consolidated financial statement continue inventory inventory value low cost market cost determine lastin firstout lifo method substantial portion inventory locate cost inventory determine firstin firstout method fifo depreciation property equipment depreciation provide estimate useful life property generally use straightline method useful live new property acquisition generally follow asset category ear building build improvement equipment scheringplough review carry value property equipment indication impairment accordance statement financial accounting standard sfas accounting impairment disposal longlive asset depreciation expense million million million depreciation expense include accelerate depreciation relate manufacturing streamline million foreign currency translation net asset scheringplough international subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation account include comprehensive incomeloss reflect separate component shareholder equity remain international subsidiary nonmonetary asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include statement consolidated operation exchange gain loss arise translate intercompany balance longterm investment nature record foreign currency translation account transactional exchange gain loss include incomeexpense net revenue recognition scheringploughs pharmaceutical product sell direct purchaser include wholesaler retailer certain health maintenance organization price discount rebate sale pay federal state agency indirect purchaser market participant manage care organization indemnify beneficiary health plan pharmaceutical cost pharmacy benefit manager scheringplough recognize revenue title risk loss pass purchaser reliable estimate follow determined commercial discount rebate arrangements rebate obligation certain federal state governmental program iii sale return normal course business table content note consolidated financial statement continue recognize revenue scheringplough estimate record applicable commercial governmental discount rebate sale return expect grant product sell period amount deduct sale period reliable estimate item scheringplough defer recognition revenue estimate record prior period reevaluate process earning common share dilute earningsloss common share compute divide net incomeloss available common shareholder plus preferred stock dividend dilutive effect mandatory convertible preferred stock sum weight average number common share outstanding plus dilutive effect share issuable defer stock unit exercise stock option dilutive effect share issuable conversion scheringplough mandatory convertible preferred stock basic earningsloss common share compute divide net incomeloss available common shareholder weight average number common share outstanding goodwill intangible asset financial accounting standard board fasb statement financial accounting standard sfas goodwill intangible asset require intangible asset acquire individually group asset initially recognize measure base fair value intangible finite life amortize useful life intangible indefinite life include goodwill amortize company assess recoverability carrying value goodwill intangible asset indefinite useful life annually event change circumstance indicate carry asset fully recoverable recoverability goodwill measure reporting unit level base twostep approach carry report unit compare fair value estimate future net discount cash flow expect generate reporting unit extent carry value report unit exceed fair value report unit second step perform reporting unit asset liability fair value extent report unit carry value goodwill exceed imply fair value goodwill impairment exist recognize recoverability intangible asset indefinite useful life measure comparison carry intangible asset fair value respective intangible asset excess carrying value intangible asset fair value intangible asset recognize impairment loss scheringplough conduct annual impairment testing goodwill october year base impairment test perform impairment goodwill assurance future goodwill indefinite live asset impairment test result charge statement consolidated operation scheringplough goodwill intangible asset balance increase significantly acquisition obs note acquisition note goodwill intangible asset additional information asset include asset capitalize software million million december respectively amortization expense million million million respectively table content note consolidated financial statement continue income taxis scheringplough implement provision fasb interpretation accounting uncertainty income taxis fin january fin order recognize uncertain tax benefit taxpayer likely sustain position measurement benefit calculate large percent likely realize resolution benefit defer income taxis recognize future tax effect temporary difference financial income tax reporting basis scheringplough asset liability base enact tax law rate accounting sharebase compensation prior january scheringplough account stockbase compensation arrangement intrinsic value method sharebase employee compensation cost reflect statement consolidated operation scheringplough defer stock unit performance plan stock option grant plan exercise price equal market value underlie common stock date grant effective january scheringplough account sharebase compensation accordance sfas revise sharebased payment sfas note sharebase compensation additional information shipping handling expense shipping expense classify sell general administrative expense consolidate statement operation impact recently issue accounting pronouncement september fasb issue sfas fair value measurement standard define fair value establishe framework measure fair value accordance generally accept accounting principle expand disclosure fair value measurement standard codifie definition fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date standard clarifie principle fair value base assumption market participant use price asset liability establish fair value hierarchy prioritize information develop assumption calendar year company standard effective beginning january nonfinancial item measure nonrecurre basis effective begin january base scheringploughs current financial position impact standard consolidated financial statement expect material november fasb issue emerge issue task force issue eitf account defer compensation postretirement benefit aspect collateral assignment splitdollar life insurance arrangement effective calendar year company january task force conclude employer recognize liability postretirement benefit relate collateral assignment splitdollar life insurance arrangement accordance fasb statement apb opinion base substantive agreement employee task force conclude employer recognize measure asset base nature substance collateral assignment splitdollar life insurance arrangement impact standard consolidated financial statement expect material february fasb issue sfas fair value option financial asset financial liabilitiesincluding amendment fasb statement sfas permit entity choose measure financial instrument certain item fair value sfas table content note consolidated financial statement continue include amendment sfas account certain investment debt equity security apply entity availableforsale trading security statement effective begin entity fiscal year begin november base scheringploughs current financial position impact standard consolidated financial statement expect material june fasb issue eitf issue account nonrefundable advance payment good service receive use future research development activity effective calendar year company january task force conclude nonrefundable advance payment good service render future research development activity defer capitalize amount recognize expense relate good deliver service perform good service long expect provide impact standard consolidated financial statement expect material december fasb issue eitf issue accounting collaborative arrangement effective calendar year company january task force clarify manner cost revenue share payment receive partner collaborative arrangement present income statement set forth certain disclosure require partner financial statement scheringplough currently assess potential impact implement standard december securities exchange commission sec issue staff accounting bulletin sab permit entity certain circumstance continue use simplified method estimate expect term plain option discuss sab accordance sfas guidance release effective january impact standard consolidated financial statement expect material december fasb issue sfas revise business combination sfas calendar year company standard applicable new business combination occur january sfas require acquire entity recognize asset acquire liability assume transaction acquisitiondate fair value limit exception significantly sfas require acquisition cost generally expense incur certain acquire contingent liability record fair value acquire inprocess research development record fair value indefinitelive intangible asset acquisition date standard impact certain unresolved matter relate purchase transaction consummate prior effective date standard scheringplough currently assess potential impact implement standard december fasb issue sfas noncontrolle interest consolidate financial statement amendment arb effective fiscal year interim period fiscal year begin december standard establish new accounting reporting standard noncontrolle interest subsidiary deconsolidation subsidiary scheringplough currently assess potential impact implement standard acquisition scheringplough acquire obs purchase price approximately euro billion cash approximately billion include legal professional fee november acquisition date acquisition add diversification market product include new therapeutic area women health central nervous system significant strength animal health product pipeline purchase method accounting account transaction accordance sfas business combination operating result obs include scheringplough consolidated financial statement period subsequent acquisition date table content note consolidated financial statement continue follow table provide pro forma financial information year end december acquisition occur begin period present dollar million share datum unaudite net sale net loss cumulative effect change accounting principle net loss available common shareholder dilute loss common share basic loss common share pro forma financial information period present include amortization stepup inventory billion acquire inprocess research development charge billion nonrecurring charge directly attributable accounting acquisition pro forma financial information include effect purchase accounting adjustment additional amortization expense acquire identifiable intangible asset depreciation stepup property effect give pro forma financial information synergistic benefit realize cost relate integration obs pro forma financial information consider indicative actual result achieve acquisition consummate date indicate purport indicate result operation future date future period preliminary allocation purchase price obs november follow ollar million cash current asset exclude inventory inventory property identifiable intangible asset goodwill othernon current asset acquire inprocess research development iprd total asset acquire acquisition relate liability current liability defer tax liability othernon current liability total liability assume net asset acquire allocation purchase price subject finalization scheringplough management analysis fair value asset acquire include asset relate pension plan liability assume obs acquisition date final allocation purchase price result additional adjustment record amount asset liability result adjustment depreciation amortization acquire inprocess research development adjustment arise finalization purchase price allocation impact cash flow adjustment result material increase decrease net incomeloss available common shareholder revision purchase price allocation additional information available final allocation expect complete soon practicable later month acquisition date table content note consolidated financial statement continue preliminary purchase price allocation identifiable intangible asset follows weight average dollar million amortization period year intangible asset determinable live patent trademark total intangible asset weight average life billion total intangible approximately year intangible asset significant residual value acquire intangible asset determine indefinite life billion goodwill assign human prescription pharmaceutical segment million assign animal health segment goodwill deductible income tax purpose preliminary value billion assign acquire iprd charge operation fourth quarter charge associate research project animal health research project womens health central nervous system anesthesia therapeutic area human health determine discount cash flow projection identify research project technological feasibility establish alternative future use discount rate range percent percent project launch date follow fda regulatory approval year time scheringplough expect project begin generate cash flow cost complete research project depend project bring final stage development ultimately submit fda regulatory agency approval december estimate cost complete project near final stage development excess million research development project consider valuation subject normal risk uncertainty associate demonstrate safety efficacy require obtain fda regulatory approval include acquisition relate liability involuntary termination benefit cost exit certain activity obs conjunction obs acquisition scheringplough agree div certain asset regulatory review europe asset classify held sale include current asset consolidate balance sheet material special acquisition relate charge manufacture streamline special acquisition relate charge year end december scheringplough incur million special acquisitionrelate charge comprise million integrationrelate cost obs acquisition million severance charge integration activity manufacturing streamline scheringplough implement change manufacture operation puerto rico new jersey streamline global supply chain enhance scheringplough longterm competitiveness change result phaseout closure scheringplough manufacturing operation manati puerto rico additional workforce reduction las piedras puerto rico new table content note consolidated financial statement continue jersey total action result elimination position action yield annualize cost saving approximately million special charge special charge relate change scheringploughs manufacturing operation total million charge consist approximately million severance million fix asset impairment cost sale include cost sale approximately million consist million accelerate depreciation million inventory writeoff million charge relate closure scheringplough manufacturing facility manati puerto rico follow table summarize activity reflect consolidated financial statement relate change scheringploughs manufacturing operation complete harge include special total cash noncash accrue cost sale charge charge payment charge liability dollar millions accrue liability january severance asset impairment accelerate depreciation inventory writeoff total accrue liability december severance accrue liability december special charge activity special charge incur follow dollar million litigation charge employee termination cost asset impairment charge litigation charge litigation reserve increase million increase result total reserve million massachusetts investigation investigation state litigation disclose awp litigation investigation note legal environmental regulatory matter represent scheringplough current estimate resolve matter august scheringplough announce reach agreement attorney office district table content note consolidated financial statement continue massachusetts department justice settle massachusetts investigation aggregate million pay settlement relate massachusetts investigation awp investigation litigation ongoing employee termination cost employee termination cost consist million associate voluntary early retirement program verp million employee termination cost asset impairment charge year end december scheringplough recognize asset impairment charge million relate primarily consolidation scheringplough biotechnology organization equity income scheringplough merck inc merck enter separate set agreement jointly develop market certain product include cholesterollowere drug allergyasthma drug december cholesterol agreement expand include country world japan general company agree collaborative activity agreement operate virtual joint venture maximum degree possible rely respective infrastructure company agreement generally provide equal sharing development cost copromotion approve product company cholesterol agreement provide scheringplough merck jointly develop commercialize ezetimibe cholesterol management field oncedaily monotherapy manage zetia asia ezetrol europe coadministration approve statin drug iii fixedcombination tablet ezetimibe simvastatin zocor merck cholesterolmodifye medicine combination medication ezetimibesimvastatin manage vytorin inegy international country zetiaezetrol ezetimibe vytorininegy combination ezetimibesimvastatin approve use launch international market scheringplough utilize equity method accounting recording share activity merckscheringplough cholesterol joint venture scheringplough net sale include sale joint venture cholesterol joint venture agreement provide share operating income generate joint venture base percentage vary product sale level country market scheringplough receive great share profit million annual zetia sale million annual zetia sale merck scheringplough generally share profit equally scheringplough allocation joint venture income increase milestone recognize company share joint venture income operation subject reduction company fail perform specify minimum number physician detail particular country company agree annually minimum number physician detail country company bear cost general sale force commercial overhead marketing joint venture product world canada puerto rico cholesterol agreement provide reimbursement company physician detail set annual basis italy contractual include profit sharing calculation reimburse canada puerto rico equal company physician detail multiply contractual fix fee scheringplough report amount equity income cholesterol joint venture amount represent reimbursement specific incremental identifiable cost schering table content note consolidated financial statement continue plough detail cholesterol product market addition amount reflective scheringplough sale effort relate joint venture scheringplough sale force relate cost associate joint venture generally estimate high year end december scheringplough recognize milestone million milestone relate certain european approval vytorin ezetimibesimvastatin cost joint venture company contractually share portion manufacturing cost specifically identify promotion cost include directtoconsumer advertising direct identifiable outofpocket promotion agree cost specific service market support market research market expansion specialty sale force physician education program certain specify research development expense generally share equally scheringplough merck certain condition specify joint venture agreement merck scheringplough entitle receive reimbursement future research development expense million follow information provide summary component scheringploughs equity income cholesterol joint venture year end december dollar millions scheringploughs share net income include milestone contractual amount physician detail elimination intercompany profit net total equity income merckscheringplough joint venture equity income joint venture exclude profit arise transaction scheringplough joint venture time underlying profit realize joint venture transaction party scheringplough merck virtual nature cholesterol joint venture scheringplough incur substantial cost sell general administrative cost reflect equity income bear overall cost structure scheringplough cost report respective line item statement consolidated operation separately identifiable cholesterol agreement provide jointly own facility product result joint venture manufacture facility own scheringplough merck allergyasthma agreement provide joint development marketing company oncedaily fixedcombination tablet contain claritin singulair singulair merck oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis new drug application filing combination tablet accept food drug administration fda standard review scheringplough announce agree merck commence development singletablet combination ezetimibe atorvastatin treatment elevate cholesterol level note legal environmental regulatory matter discussion enhance matter sharebase compensation prior january scheringplough account stock compensation arrangement intrinsic value method follow recognition measurement principle apb opinion accounting stock issue employee relate interpretation prior stockbase employee compensation cost reflect statement consolidated operation table content note consolidated financial statement continue scheringplough defer stock unit stock option grant plan exercise price equal market value underlie common stock date grant scheringplough adopt sfas effective january sfas require company recognize compensation expense equal fair value sharebase payment grant employee scheringplough elect modify prospective transition method adjustment prior period require result adopt sfas method provision sfas apply award grant date adoption unrecognized expense awards unveste date adoption base grant date fair value sfas amend sfas statement cash flow require excess tax benefit reflect operate cash flow reflect finance cash flow grant issue retirementeligible employee prior adoption sfas scheringplough recognize compensation cost state vest period stock option defer stock unit acceleration unrecognize compensation cost retirement employee adoption sfas scheringplough recognize compensation cost sharebase grant january service period early year employee retirement eligible year grant employee retirement eligibility date year grant iii service period award november financial accounting standard board fasb issue fasb staff position fas transition election relate accounting tax effect sharebase payment award scheringplough elect adopt transition method provide fasb staff position purpose calculate pool excess tax benefit available absorb tax deficiency recognize subsequent adoption sfas stock incentive plan plan approve scheringplough shareholder term plan million scheringplough authorize common share grant stock option award deferred stock unit officer certain employee scheringplough december scheringplough intend utilize unissued authorized share satisfy stock option exercise issuance defer stock unit expense related sharebased compensation classify line item associate employee function scheringplough grant performancebase deferred stock unit stock incentive plan provide certain senior manager opportunity earn share scheringplough common stock unit earn specific preestablishe level performance service achieve year performance period implementation sfas quarter scheringplough recognize benefit income million cumulative effect change accounting principle relate longterm compensation plan require account liability plan sfas tax benefit recognize related stockbased compensation relate cash flow impact material scheringplough net operating loss position stock option stock option grant employee exercise price equal fair market value scheringplough stock date grant stock option plan generally vest year term seven year certain option grant previous plan vest long period range year term year compensation cost stock option recognize table content note consolidated financial statement continue requisite service period separately vest portion stock option award expense recognize net estimate forfeiture vest period option accelerated method expense recognize approximately million respectively weightedaverage assumption blackschole optionprice model follow dividend yield volatility riskfree interest rate expect term option year dividend yield base historical dividend yield expect volatility base historical volatility scheringplough common stock expect differ materially future volatility riskfree interest rate base treasury yield curve effect time grant period correspond expect life option expect term option represents weight average period time option grant expect outstanding give consideration vest schedule schere plough utilize simplified method calculate expect term stock option allow sab amend sab cash receive exercise stock option million million million respectively stockbase compensation prior january determine intrinsic value method follow table provide supplemental information stockbase compensation compute sfas dollar million share figure net income available common shareholder report add expense include report net income defer stock unit deduct pro forma expense stock option defer stock unit charge net income available common shareholder accordance sfas pro forma net income available common shareholder fair value method dilute earning common share dilute earning common share report pro forma diluted earning common share fair value method basic earning common share basic earning common share report pro forma basic earning common share fair value method table content note consolidated financial statement continue summarize information stock option outstanding exercisable december follow tstande exerc able weighted weight weight number average average number average remain exercise exercise exercise price range option term year price option price thousand thousand weightedaverage fair value stock option grant respectively intrinsic value stock option exercise million million million respectively total fair value option vest million million million respectively december total remain unrecognized compensation cost relate nonveste stock option amount million amortize weightedaverage remain requisite service period year follow table summarize stock option activity december change year end current prior plan eighte number average exercise option price thousand outstanding january grant exercise cancel expire outstanding december exercisable december aggregate intrinsic value stock option outstanding december million aggregate intrinsic value stock option currently exercisable december million intrinsic value stock option calculate base exercise price underlie award quote price scheringplough common stock reporting date table content note consolidated financial statement continue follow table summarize nonveste stock option activity december change year end current prior plan eighte number average fair option value thousand nonveste january grant vested forfeited nonveste december defer stock unit fair value defer stock unit determine base number share grant quote price scheringplough common stock date grant defer stock unit generally vest end year provide employee remain service scheringplough expense recognize straightline basis vest period defer stock unit payable equivalent number common share expense recognize million million million respectively summarize information defer stock unit outstanding december follow stand weight number average weight defer stock remain average defer stock unit price range unit term year fair value thousand weightedaverage fair value defer stock unit grant respectively total fair value defer stock unit vest million million million respectively december total remain unrecognized compensation cost relate deferred stock unit amount million amortize weightedaverage remain requisite service period year table content note consolidated financial statement continue follow table summarize defer stock unit activity december change year end current prior plan number nonveste weight defer stock average unit fair value thousand nonveste january grant vested forfeited nonveste december performancebase deferred stock unit distribution performancebase defer stock unit contingent scheringplough meeting performance andor market condition half performancebase stock unit grant performance condition fair value unit base close stock price date grant half grant market condition fair value unit determine lattice valuation model expect volatility assumption assumption appropriate determine fair value weight average grantdate fair value performancebase deferred stock unit grant represent approximately underlie share december unit vest compensation expense performancebase stock unit base fair value award expect vest base performance measure recognize performance period compensation expense recognize year end million december unrecognized compensation cost relate performancebase deferred stock unit million amortize remain weight average requisite service period year remain unrecognized compensation cost performancebase deferred stock unit vary report period base change expect achievement performance measure liability plan scheringplough compensation plan classify liability plan sfas ultimate cash payout plan base scheringploughs stock performance compare stock performance peer group adoption sfas january scheringplough recognize cumulative income effect change accounting principle million order recognize liability plan fair value service period income expense amount relate liability plan base change fair value report date fair value plan estimate lattice valuation model expect volatility assumption assumption appropriate determine fair value liability plan service period conclude december value plan fix expense recognize liability plan statement consolidated operation exclusive impact cumulative effect change accounting principle million million respectively december total remain unrecognized compensation cost relate liability plan amount million amortize weightedaverage remain requisite service period year vary reporting period base change fair value plan remain service requirement table content note consolidated financial statement continue incomeexpense net component incomeexpense net follow dollar million interest cost incur capitalize construction interest expense interest income foreign exchange gainslosse net realize gain foreign currency option net ineffective portion interest rate swap net total incomeexpense net net foreign exchange gain million include million foreign currency transaction exchange loss relate euro denominate debt instrument prior account economic hedge net investment foreign operation currency exchange loss noncash item include adjustment reconcile net loss net cash provide operating activity statement consolidated cash flow overall risk management strategy consideration preliminary financing scenario associate acquisition obs scheringplough purchase eurodenominate currency option derivative aggregate premium approximately million receive proceed million termination option result net realize gain million derivative qualify hedge accounting accordance sfas accounting derivative instrument hedge activity amend sfas accordingly gain derivative recognize statement consolidated operation derivative shortterm trading nature hedge specific financing invest transaction accordingly cash impact derivative classified operating cash flow statement consolidated cash flow scheringplough execute series interest rate swap anticipation financing acquisition obs objective swap hedge interest rate payment future issuance debt swap designate cash flow hedge future interest rate payment accordance sfas effective portion gain loss hedge report comprehensive income ineffective portion report operation connection eurodenominate debt issuance describe note borrowing commitment portion swap deem ineffective scheringplough recognize million loss statement consolidated operation effective portion swap million record comprehensive income recognize interest expense life relate debt cash flow impact interest rate swap classify operating cash flow statement consolidated cash flow scheringplough participate healthcare refinancing program adopt local government fiscal authority major european market year end december scheringplough transfer million trade account receivables own foreign subsidiary thirdparty financial institution recourse year end december scheringplough transfer million trade account receivables own foreign subsidiary thirdparty financial institution recourse transfer trade account receivable qualified sale account receivable sfas accounting transfer service financial asset extinguishment liability year end december transfer trade account receivable table content note consolidated financial statement continue material impact scheringplough statement consolidated operation cash flow transaction include change account receivable operating activity income taxis component consolidate lossincome income taxis year end december follow dollar millions united states foreign total lossincome income taxis include cumulative effect change accounting principle loss include acquire inprocess research development charge amortization fair value certain asset acquire obs acquisition income cholesterol joint venture include table base jurisdiction income earn component income tax expense year end december follow deral tate reign otal dollar millions current defer total current defer total current defer total scheringplough establish valuation allowance net defer tax asset include benefit operating loss management conclude likely benefit net defer tax asset realize december scheringplough continue maintain valuation allowance net defer tax asset scheringplough repatriate approximately billion accordance plan repatriation provision american job creation act ajca maximum foreign earning qualify effectively reduce tax rate percent tax provision relate ajca record scheringplough tax provision year end december include federal income tax benefit approximately million result irs notice issue august provision notice result reduction previously accrue tax liability attributable ajca repatriation reduce net operating loss nol carry forward subsequent year table content note consolidated financial statement continue prior ajca scheringplough intent indefinitely reinvest unremitted earning international subsidiary amount repatriate ajca scheringplough maintain intent indefinitely reinvest earning international subsidiary scheringplough provide defer taxis approximately billion undistributed foreign earning december determine tax liability arise earning remit practicable liability depend number factor include earning distribute operation generate taxable profit loss defer income taxis provide temporary difference financial reporting basis tax basis scheringplough asset liability scheringplough defer tax asset result principally record certain item currently deductible tax purpose net operating loss tax credit carryforward scheringplough defer tax liability principally result book tax basis difference result obs acquisition use accelerate depreciation tax purpose component scheringplough defer tax asset liability december follow dollar million defer tax asset nol carryforward tax credit carryforward postretirement employee benefit inventory relate sale return reserve litigation accrual intangible asset total defer tax asset defer tax liability depreciation inventory valuation obs intangible asset total defer tax liability defer tax valuation allowance net defer tax liabilitiesasset change valuation allowance principally relate increase defer tax liability relate acquisition obs defer tax asset net operating loss tax credit carryforward principally relate nol research development tax credit foreign tax credit federal alternative minimum tax amt credit carryforward december scheringplough approximately billion nol income tax purpose available offset future taxable income nol operate loss adjust difference financial tax report nol expire vary amount unused state nol relate nol incremental relate obss state nol expire vary amount december scheringplough approximately million tax credit table content note consolidated financial statement continue carryforward expire million foreign tax credit carryforward expire million amt tax credit carryforward indefinite life nol carryforward materially reduce examination scheringplough income tax return internal revenue service irs scheringplough reduce defer tax asset relate valuation allowance record nol tax credit carryforward reflect estimate resolution examination difference income taxis base statutory tax rate scheringploughs income tax expense year end december follow dollar million income tax benefitexpense statutory rate increasedecrease taxis result low rate jurisdiction net federal benefit repatriate foreign earning act net credit operating loss tax benefit record permanent difference state income tax provision tax matter income tax effective tax rate permanent difference largely attributable acquire inprocess research development charge billion relate acquisition obs tax benefit record low tax rate jurisdiction net primarily attributable scheringplough manufacturing subsidiary singapore ireland puerto rico operate incentive tax grant begin expire additionally major country schere plough conduct operation statutory tax rate tax rate overall income taxis primarily relate foreign taxis include benefit relate operating loss scheringplough implement provision fasb interpretation accounting uncertainty income taxis fin january require fin cumulative effect apply provision interpretation report adjustment scheringplough retain earning balance january scheringplough reduced january retain earning million result adoption fin scheringploughs unrecognized tax benefit result primarily vary application statute regulation interpretation include exposure intercompany term cross border arrangement utilization cash hold foreign subsidiary investment property scheringplough tax matter litigation note legal environmental regulatory matter january december total unrecognized tax benefit million million respectively include reduction defer tax asset carry valuation allowance potential refund claim tax liability january december approximately million million respectively total unrecognized tax benefit recognize affect effective tax rate management believe reasonably possible total unrecognized tax benefit decrease twelvemonth period million primarily attributable decision tax matter currently litigate newark district court possible final resolution scheringplough examination irs appeal possible resolution matter time ultimate resolution scheringplough tax matter payment receipt relate cash dependent number factor outside scheringploughs control table content note consolidated financial statement continue scheringplough include interest expense income potential penalty uncertain tax position component income tax expense statement consolidated operation total accrue interest relate uncertain tax position january december million million respectively include accrue liability tabular reconciliation scheringploughs fin unrecognized tax benefit january december follow ollar millions january addition tax position relate addition tax position relate prior year addition tax position relate acquire entity reduction tax position relate prior year reduction potential refund claim reduction relate amount settle tax authority lapse statute limitation december schere plough consider file refund claim base court decision involve claim right doctrine recent court appeal decision clarify law area clear schering plough prevail claim unrecognized tax benefit reduce accordingly impact net loss net consolidated income tax payment exclusive payment relate tax examination litigation discuss million million million respectively january irs complete examination scheringplough federal income tax return scheringplough cash payment quarter form tax deposit approximately million anticipation settlement tax examination prevent additional irs interest charge payment fully satisfied liability associate tax examination consistent previously record reserve second quarter irs complete examination scheringplough federal income tax return schere plough seek resolution issue raise examination irs administrative appeal process scheringplough remain open irs tax year significant tax jurisdiction state foreign scheringploughs income tax return open examination period july scheringplough payment million irs pertaining examination october irs auditor assert interest rate swap scheringplough enter unrelated party recharacterize loan affiliate company result additional tax liability tax year september scheringplough payment irs million income tax million interest scheringplough file refund claim tax interest irs december follow irss denial scheringplough claim refund scheringplough file suit district court district new jersey refund tax interest refund litigation currently try newark district court scheringplough tax reserve adequate cover abovementione payment table content note consolidated financial statement continue retirement plan postretirement benefit plan description scheringplough define benefit pension plan cover eligible employee certain foreign country large plan scheringplough retirement plan benefit normal retirement primarily base participant average final earning year service social security income modify early retirement death disability benefit available plan benefit fully vest year service plan provide continue accrual credit service employee opt postpone retirement remain employed scheringplough reach normal retirement age nonus pension plan offer benefit competitive local market condition define benefit plan assume scheringplough obs acquisition include scheringploughs result operation acquisition date financial position december note acquisition addition scheringplough provide postretirement medical life insurance benefit primarily eligible retiree dependent postretirement benefit plan effective december scheringplough account retirement plan postretirement benefit plan plan accordance sfas employer account define benefit pension postretirement plan sfas amendment sfas sfas require recognition asset overfunde plan liability underfunde plan scheringplough consolidated balance sheet statement require recognition change fund status plan year change occur sfas allow extended adoption date requirement scheringploughs yearend date measurement date define benefit pension postretirement plan plan measurement date yearend prior adoption sfas scheringplough adopt yearend measurement date effective impact consolidate financial statement relate measurement date change material incremental effect result implementation sfas individual line item scheringplough consolidated balance sheet december follow balance sheet balance sheet amount prior amount sfas sfas sfas sfas adjustment adjustment adjustment adjustment dollar million asset intangible asset longterm asset include defer tax asset liability accrue compensation longterm liabilities equity accumulate comprehensive loss net tax effect include scheringplough accumulate comprehensive loss december million million net tax effect million million net tax effect respectively cost recognize component net periodic benefit cost pursuant table content note consolidated financial statement continue sfas employer account pension sfas employer account postretirement benefit pension component cost december follow oth post retirement plan retirement benefit dollar million actuarial loss prior service costcredit total actuarial loss primarily represent cumulative difference actuarial assumption actual return plan asset change discount rate plan experience total loss amount net excess certain threshold amortize net pension postretirement benefit cost average remain service life employee amount accumulate comprehensive loss expect recognize component net periodic cost follow retirement postretirement plan benefit dollar million actuarial loss recognition prior service costcredit recognition actuarial assumption consolidated weight average assumption determine benefit obligation december oth pos retirement retirement plan benefit discount rate rate increase future compensation assumption develop benefit obligation yearend consolidated weight average assumption determine net benefit cost year end december oth pos tret emen retirement plan benefit discount rate longterm expect rate return plan asset rate increase future compensation assumption determine net periodic benefit cost year establish end previous year assumption determine benefit obligation establish yearend net periodic benefit cost actuarial present value benefit obligation base actuarial assumption determine annually base evaluation longterm trend market condition impact cost provide retirement benefit longterm expect rate return plan asset derive return assumption determine major asset class equity fix income real estate proportional basis return table content note consolidated financial statement continue expectation asset class base largely assumption economic growth inflation support longterm historical datum weight average assume healthcare cost trend rate postretirement measurement purpose percent trend percent percent increase assume healthcare cost trend rate increase combined post retirement service interest cost million postretirement benefit obligation million percent decrease assume health care cost trend rate decrease combined postretirement service interest cost million postretirement benefit obligation million average retirement age assume base annual rate retirement experience scheringplough component net periodic benefit cost net pension postretirement benefit cost total million million million respectively component net pension postretirement benefit expense follow pos tre remen retirement plan benefit dollar million service cost interest cost expect return plan asset amortization net termination benefit settlement net pension postretirement benefit cost table content note consolidated financial statement continue benefit obligation component change benefit obligation follow ther postretirement retirement plan benefit dollar million benefit obligation begin year service cost interest cost medicare drug subsidy receive participant contribution effect exchange rate change benefit pay acquisitionsplan transfer actuarialgain loss include assumption change change measurement date plan amendment termination benefit curtailment settlement benefit obligation end year benefit obligation overfunde plan benefit obligation underfunde plan fund status balance sheet presentation component change plan asset follow ther postretirement retirement plan benefit dollar million fair value plan asset primarily stock bond begin year actual gain plan asset employer contribution participant contribution acquisitionsplan transfer effect exchange rate change settlement benefit pay fair value plan asset end year plan asset overfunde plan plan asset underfunde plan table content note consolidated financial statement continue increase benefit obligation retirement plan asset december primarily acquisition andor plan transfer relate scheringplough acquisition obs november obs benefit obligation retirement plan asset base preliminary estimate fair value addition plan asset indicate december security investment million million respectively hold nonqualified trust designate provide pension benefit certain underfunde plan accordance sfas december net asset overfunde plan million million respectively relate scheringplough retirement plan include longterm asset net liability underfunde plan december total billion billion respectively follow ther postretirement retirement plan benefit dollar millions accrue compensation current longterm liability total december accumulate benefit obligation abo retirement plan billion billion respectively aggregate accumulate benefit obligation fair value plan asset retirement plan accumulate benefit obligation excess plan asset billion billion respectively december billion billion respectively december plan asset fair value asset allocation consolidated retirement plan december target allocation follow ntage target plan asset allocation december asset category equity security debt security real estate total asset allocation postretirement benefit trust december target allocation follow ntage target plan asset allocation december asset category equity security debt security total scheringplough investment relate plan broadly diversify consist primarily equity fix income security objective generate longterm investment return table content note consolidated financial statement continue consistent acceptable level overall portfolio market value risk asset periodically rebalance target allocation estimate future benefit payment follow benefit payment reflect expect future service appropriate expect pay retirement postretirement plan benefit dollar million year scheringplough practice fund qualified pension plan sufficient amount meet minimum requirement set forth applicable law scheringplough expect contribute approximately million retirement plan include minimum approximately million scheringplough retirement plan define contribution plan scheringplough maintain define contribution saving plan include plan acquire obs acquisition large plan scheringplough make contribution plan equal percent eligible employee earning plus matching contribution percent eligible employee earning base employee contribution total scheringplough contribution plan million million respectively scheringplough maintain define contribution retirement plan jurisdiction scheringplough contribution plan material earning common share follow table reconcile component basic dilute earningsloss share computation dollar share millions eps numerator net lossincome available common shareholder eps denominator weight average share outstanding basic eps dilutive effect option defer stock unit average share outstanding diluted eps quarter scheringplough mandatory convertible preferred stock convert million common share common share include weight average share calculation period conversion table content note consolidated financial statement continue year end december million million million common share respectively obtainable conversion mandatory convertible preferred stock exclude computation dilute lossearning common share effect antidilutive weight average basis period prior conversion addition year end december approximately million common share obtainable conversion mandatory convertible preferred stock exclude computation dilute lossearning common share effect antidilutive equivalent common share issuable scheringploughs stock incentive plan exclude computation dilute lossearning common share effect antidilutive million million million respectively year end december respectively scheringplough issue common share august common share include weightedaverage share calculation period issuance note shareholder equity additional information accumulate comprehensive loss component accumulate comprehensive loss december follow dollar million foreign currency translation adjustment pension otherpostretirement liability net tax effect accordance sfas provision accumulate derivative loss unrealize gain investment available sale net tax total note retirement plan postretirement benefit additional information impact scheringplough financial statement adoption sfas include foreign currency translation adjustment million charge comprehensive loss scheringplough eurodenominate debt instrument designate effective economic hedge net investment foreign operation effective december scheringplough account retirement postretirement benefit plan accordance sfas implementation sfas result increase million net tax effect accumulate comprehensive loss reduce shareholder equity scheringplough execute series interest rate swap anticipation financing acquisition obs objective swap hedge interest rate payment future issuance debt swap designate cash flow hedge future interest rate payment accordance sfas effective portion gain loss hedge report comprehensive income ineffective portion report operation effective portion swap million record comprehensive income recognize interest expense life relate debt year end december million effective portion interest rate swap recognize interest expense million expect recognize interest expense table content note consolidated financial statement continue gross unrealized pretax gain investment million million respectively unrealize loss immaterial inventory inventory consist follow december dollar million finish product good process raw material supply total inventory inventory classify noncurrent asset include asset december million million respectively inventory expect sell year inventory value lastin firstout lifo basis comprise approximately percent percent total inventory december respectively estimate replacement cost total inventory december billion billion respectively cost inventory determine firstin firstout method fifo goodwill intangible asset purchase accounting acquisition obs scheringplough record billion goodwill billion assign human prescription pharmaceutical segment million assign animal health segment goodwill relate obs acquisition deductible income tax purpose follow table summarize goodwill activity year end december human human prescription animal prescription animal pharmaceutical health total pharmaceutical health total dollar million goodwill balance january acquisition foreign exchange writeoff goodwill balance december table content note consolidated financial statement continue component intangible asset net follow december gross gross carrying accumulate carry accumulate amortization net amortization net dollar million patent trademark license total intangible asset patent trademark license amortize straightline method respective useful life residual value intangible asset estimate zero purchase accounting acquisition obs scheringplough record billion intangible asset note acquisition additional information amortization expense relate intangible asset million million million respectively include cost sale statement consolidated operation intangible asset review determine recoverability compare carry value expect undiscounted future cash flow event circumstance warrant review annual amortization expense relate intangible asset year expect approximately million product license august scheringplough exercise right develop commercialize centocor inc centocor golimumab new anti tnfalpha monoclonal antibody develop therapy treatment rheumatoid arthritis immunemediate inflammatory disease pursuant exercise scheringplough receive exclusive worldwide marketing right golimumab exclude japan china include hong kong taiwan indonesia exchange right agreement scheringplough upfront payment million centocor tax benefit million payment include research development expense year end december scheringplough sharing development cost centocor december scheringplough centocor revise distribution agreement development commercialization distribution remicade golimumab extend scheringploughs right exclusively market remicade match duration scheringplough exclusive marketing right golimumab effective regulatory approval golimumab scheringploughs marketing right product extend year commercial sale golimumab centocor receive progressively increase share profit scheringplough distribution product scheringplough marketing territory share profit remain fixed remainder term change duration remicade marketing right profit share arrangement product condition approval golimumab grant prior september scheringplough independently develop market golimumab crohns disease indication territory option centocor participate addition scheringplough centocor agree utilize autoinjector device commercialization golimumab agree share development cost right device scheringplough upfront payment million include research development expense year end december effective september scheringplough restructure integrilin copromotion agreement millennium term restructure agreement scheringplough acquire exclusive table content note consolidated financial statement continue development commercialization right integrilin exchange upfront payment million royalty integrilin sales scheringplough agree pay minimum royalty million year millennium scheringplough purchase exist integrilin inventory millennium million upfront payment capitalize include intangible asset borrowing commitment short longterm borrowing scheringplough outstanding borrowing december follow dollar millions shortterm commercial paper shortterm borrowing current portion longterm debt current portion capital lease total shortterm borrowing longterm senior unsecured eurodenominate note float rate eurodenominate term loan senior unsecured note senior unsecured eurodenominate note senior unsecured note senior unsecured note senior unsecured note capital lease longterm borrowing total longterm borrowing scheringplough shortterm borrowing consist primarily bank loan commercial paper issue weight average interest rate shortterm borrowing percent percent december respectively senior unsecured note october scheringplough issue euro million aggregate principal percent senior unsecured euro denominate note euro billion aggregate principal percent senior unsecured eurodenominate note net proceed offer approximately billion interest note payable annually effective interest rate percent senior unsecured eurodenominate note percent senior unsecured eurodenominate note incorporate initial discount debt issuance fee impact interest rate hedge percent percent respectively interest rate payable note subject adjustment note generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidate net tangible asset note redeemable scheringplough option time redemption price specify prospectus change control trigger event occur define prospectus holder note right require scheringplough repurchase note cash table content note consolidated financial statement continue payment equal percent aggregate principal note repurchase plus accrue unpaid interest date purchase september scheringplough issue billion aggregate principal percent senior unsecured note billion aggregate principal percent senior unsecured note net proceed offer approximately billion interest note payable semiannually effective interest rate percent senior unsecured note percent senior unsecured note incorporate initial discount debt issuance fee percent percent respectively interest rate payable note subject adjustment note generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidate net tangible asset note redeemable scheringplough option time redemption price equal great percent principal note sum present value remain schedule payment principal interest discount redemption date semiannual basis rate treasury note comparable remain term plus basis point note basis point note change control trigger event occur define prospectus holder note right require scheringplough repurchase note cash payment equal percent aggregate principal note repurchase plus accrue unpaid interest date purchase scheringplough net proceed issuance senior unsecured note fund portion purchase price obs acquisition note acquisition november scheringplough issue billion aggregate principal percent senior unsecured note billion aggregate principal percent senior unsecured note net proceed offer billion interest note payable semiannually subject rate adjustment follow rating assign particular series note moodys investors service inc moodys standard poor rating service change rating set forth interest rate payable series note initial interest rate percent note percent note plus additional interest rate set forth moodys additional interest rate oodys rating rating baa bbb baa bbb baa bbb event interest rate note increase percent initial coupon rate percent percent respectively moodys subsequently upgrade rating interest rate correspondingly reduce percent percent respectively furthermore interest rate payable particular series note return percent percent respectively rate adjustment provision permanently cease apply follow downgrade moodys respectively note subsequently rate baa moodys bbb issuance note rate moodys july moodys lower rating note baa accordingly interest payable note increase basis point effective december result percent interest rate payable note percent interest rate payable note increase december note rate baa moodys table content note consolidated financial statement continue senior unsecured note redeemable scheringplough option time redemption price equal great percent principal note sum present value remain schedule payment principal interest discount rate treasury note comparable remain term plus basis point note basis point note term loan october scheringplough enter fiveyear senior unsecured eurodenominate term loan facility syndicate bank october scheringplough draw euro billion billion term loan fund portion purchase price obs acquisition note acquisition additional information new term loan float interest rate weight average rate require scheringplough maintain net debt total capital ratio percent percent net debt equal total debt cash cash equivalent shortterm investment marketable security total capital equal sum total debt total shareholder equity exclude cumulative effect acquire inprocess research development connection acquisition consummate closing term loan term loan generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidate net tangible asset addition scheringplough international subsidiary approximately million available unused line credit financial institution december aggregate maturitie aggregate maturity longterm debt year follow ereafte dollar million longterm debt credit facility august scheringplough enter billion revolving credit agreement syndicate bank terminate billion credit facility mature credit facility float interest rate mature august require scheringplough maintain net debt total capital ratio percent percent net debt equal total debt cash cash equivalent shortterm investment marketable security total capital equal sum total debt total shareholder equity exclude cumulative effect acquire inprocess research development connection acquisition consummate closing credit facility credit facility generally restrict scheringplough creating assume lien enter sale leaseback transaction aggregate outstanding indebtedness secure lien relate sale leaseback transaction exceed percent consolidate net tangible asset credit line available general corporate purpose consider support scheringplough commercial paper borrowing borrowing credit facility draw parent company whollyowne international subsidiary accompany parent guarantee facility require compensating balance nominal commitment fee pay december borrowing outstanding facility scheringplough billion credit facility terminate august december million draw facility whollyowne international subsidiary purpose table content note consolidated financial statement continue funding repatriation ajca borrowing fully repay december borrowing outstanding facility addition credit facility scheringplough enter million credit facility fourth quarter purpose funding repatriation ajca december entire draw whollyowne international subsidiary fund repatriation facility pay terminate commitment total rent expense amount million million million respectively future annual minimum rental commitment year noncancelable operating lease december follow million million million million million aggregate minimum lease obligation million december scheringplough commitment total million million relate capital expenditure respectively financial instrument sfas require derivative record balance sheet fair value addition statement require effective portion qualify cash flow hedge recognize income hedge item affect income change fair value derivative qualify fair value hedge change fair value hedge risk recognize occur change fair value derivative qualify hedge treatment ineffective portion qualifying hedge recognize statement consolidated operation occur risk policy objective scheringplough expose market risk primarily change foreign currency exchange rate less extent interest rate equity price change currently scheringplough deem cost effective engage formulabase program hedge profit cash flow international operation derivative financial instrument limit basis scheringplough hedge selective foreign currency risk derivative scheringplough international subsidiary purchase significant quantity inventory payable dollar manage level inventory relate payable rate inventory turnover provide natural level protection adverse change exchange rate furthermore risk adverse exchange rate change somewhat mitigated fact scheringplough international operation widespread scheringplough senior unsecured eurodenominate note eurodenominate term loan designate effective economic hedge net investment foreign operation accordance sfas foreign currency translation foreign currency transaction gain loss eurodenominate debt instrument include foreign currency translation adjustment comprehensive income overall risk management strategy consideration preliminary financing scenario associate acquisition obs scheringplough purchase eurodenominate currency option mitigate exposure event significant strengthening euro compare dollar scheringplough purchase option aggregate premium approximately million receive proceed million termination option result net realize gain million derivative qualify hedge accounting accordance sfas accordingly gain derivative recognize statement consolidated operation derivative shortterm trading nature hedge specific financing table content note consolidated financial statement continue investment transaction accordingly cash impact derivative classified operating cash flow statement consolidated cash flow note incomeexpense net december open foreign currency option contract scheringplough execute series interest rate swap anticipation financing acquisition obs objective swap hedge interest rate payment future issuance debt swap designate cash flow hedge future interest payment accordance sfas effective portion gain loss hedge report comprehensive income ineffective portion report operation connection eurodenominate debt issuance describe note borrowing commitment portion swap deem ineffective scheringplough recognize million loss statement consolidated operation effective portion swap million record comprehensive income recognize interest expense life relate debt cash flow related interest rate swap classify operating cash flow statement consolidated cash flow note incomeexpense net december open interest rate swap scheringplough mitigate credit risk derivative instrument deal counterpartie consider high credit quality accordingly scheringplough anticipate loss nonperformance scheringplough enter derivative instrument manner generate trading profit scheringplough classifie cash flow derivative account hedge category item hedge table present carry value estimate fair value certain scheringplough financial instrument december estimate fair value determine base market price available dealer quote carry value financial instrument include cash cash equivalent approximate estimate fair value december carry estimate carry estimate value fair value value fair value dollar million asset shortterm investment longterm investment liabilitie shortterm borrowing current portion longterm debt longterm debt longterm investment longterm investment include noncurrent asset primarily consist debt equity security hold non qualified trust fund longterm employee benefit obligation include liability consolidated balance sheet asset fund relate employee benefit obligation shareholder equity prefer share december scheringplough authorize share prefer stock consist preferred share designate percent mandatory convertible preferred stock table content note consolidated financial statement continue preferred share designation determined december share percent mandatory convertible preferred stock issue outstanding mandatory convertible preferred stock august scheringplough issue share percent mandatory convertible preferred stock prefer stock face value billion net proceed scheringplough approximately billion deducting commission discount underwriting expense scheringplough net proceed sale prefer stock fund portion purchase price obs acquisition note acquisition additional information share prefer stock automatically convert common share scheringplough depend average closing price scheringplough common share trading day period end trading day prior mandatory conversion date august define prospectus prefer shareholder elect convert time prior august minimum conversion ratio common share share prefer stock additionally time prior mandatory conversion date closing price scheringplough common share exceed trading day period consecutive trading day scheringplough elect cause conversion prefer stock outstanding minimum conversion ratio common share share preferred stock prefer stock accrue dividend annual rate percent share outstanding dividend cumulative date issuance extent scheringplough legally permit pay dividend board director declare dividend payable scheringplough pay dividend dividend payment date dividend payment date february august november year dividend pay november mandatory convertible prefer stock year end december share percent mandatory convertible preferred stock issue august preferred stock convert share scheringplough common stock follow conversion share prefer stock resume status authorize unissued preferred stock undesignate series available future issuance equity issuance treasury share august scheringplough issue common share treasury share share net proceed scheringplough approximately billion deducting commission discount underwriting expense scheringplough net proceed sale common share fund portion purchase price obs acquisition note acquisition additional information summary treasury share transaction year end december follow share millions share balance january issuance common share stock incentive plan activity share balance december include treasury share balance million share acquire subsidiary scheringplough open market purchase program share consider table content note consolidated financial statement continue treasury share new jersey law like treasury share vote consider outstanding share determine necessary vote approve matter submit stockholder vote subsidiary receive dividend share effective september board director scheringplough adopt amend restate certificate incorporation reflect automatic conversion prefer stock issue share common stock september term prefer stock insurance coverage scheringplough maintain insurance coverage deductible selfinsurance management believe adequate need current circumstance coverage reflect market condition include cost availability exist time write relationship insurance coverage selfinsurance vary accordingly scheringplough selfinsure substantial proportion risk relate product liability availability commercial insurance restrictive scheringplough continually assess good way provide insurance need segment information scheringplough reportable segment human prescription pharmaceutical animal health consumer health care segment sale lossprofit datum follow consistent scheringplough current management reporting structure human prescription pharmaceutical segment discover develop manufacture market human pharmaceutical product animal health segment discover develop manufacture market animal health product consumer health care segment develop manufacture market overthecounter foot care sun care product primarily table content note consolidated financial statement continue net sale major product segment dollar million human prescription pharmaceutical remicade nasonex pegintron temodar clarinexaerius claritin avelox integrilin rebetol caelyx intron subutexsuboxone asmanex pharmaceutical animal health consumer health care otc foot care sun care consolidate net sale net sale geographic area dollar millions united states europe canada latin america pacific area asia consolidate net sale table content note consolidated financial statement continue scheringplough subsidiary country outside net sale present geographic area scheringplough customer locate follow foreign country account percent consolidated net sale past year consolidated consolidated consolidated net sale net sale net sale net sale net sale net sale dollar million total international net sale france japan canada italy net sale customer sale single customer account percent scheringploughs consolidate net sale past year follow consolidated consolidated consolidated net sale net sale net sale net sale net sale net sale dollar million mckesson corporation cardinal health lossprofit segment year nde ecem dollar million human prescription pharmaceutical animal health consumer health care corporate include net interest income million million million respectively consolidate lossprofit tax cumulative effect change accounting principle human prescription pharmaceutical segment loss include billion purchase accounting item include acquire inprocess research development billion animal health segment loss include million purchase accounting item include acquire inprocess research development million scheringplough net sale include sale vytorin zetia manage joint venture merck scheringplough account joint venture equity method accounting note equity income additional information human prescription pharmaceutical segment include equity income merckscheringplough joint venture corporate include interest income expense foreign exchange gain loss currency option gain headquarters expense special charge miscellaneous item accounting policy table content note consolidated financial statement continue segment report describe note summary significant accounting policy corporate include special acquisition relate charge million comprise million integration relate cost obs acquisition million severance charge integration activity estimate charge relate reportable segment follow human prescription pharmaceutical million animal health million corporate million corporate include special charge million primarily relate change scheringploughs manufacturing operation puerto rico announce june relate human prescription pharmaceutical segment include cost sale charge approximately million manufacturing streamlining action primarily relate human prescription pharmaceutical segment corporate include special charge million include million employee termination cost million asset impairment charge increase litigation reserve million result total reserve million represent scheringplough current estimate resolve massachusetts investigation investigation state litigation disclose awp litigation investigation note legal environmental regulatory matter estimate charge relate reportable segment follow human prescription pharmaceutical million consumer health care million animal health million corporate million supplemental sale information sale product comprise percent scheringplough international sale year end december follow mount rcentage dollar million nasonex otc claritin international remicade longlive assets geographic location dollar millions united states netherlands ireland singapore total longlived asset show geographic location primarily intangible property significant increase longlive asset december obs acquisition scheringplough disaggregate asset segment basis internal management report information present table content note consolidated financial statement continue consent decree scheringplough agree fda entry consent decree resolve issue relate compliance current good manufacturing practice cgmp certain scheringploughs facilities new jersey puerto rico consent decree decree summary decree require scheringplough payment total million equal installment million pay addition decree require scheringplough complete revalidation program manufacturing process produce bulk active pharmaceutical ingredient finish drug product cover facility implement comprehensive cgmp work plan facility scheringplough complete requirement accordance schedule require decree obtain thirdparty certification completion work plan require decree august scheringplough announce dissolution consent decree district court district new jersey legal environmental regulatory matter background scheringplough involve claim investigation legal proceeding scheringplough record liability contingency probable liability incur reasonably estimate scheringplough adjust liability contingency reflect current good estimate probable loss minimum liability case well estimate determinable scheringplough record minimum probable range liability expect insurance recovery consider determine amount record liability environmental relate matter scheringplough believe loss contingency reasonably possible probable loss estimate liability record liability reasonably possible disclosure loss contingency scheringplough review status claim investigation legal proceeding ongoing basis include related insurance coverage time time scheringplough settle resolve matter term condition management believe good interest scheringplough resolution claim investigation legal proceeding individually aggregate material adverse effect scheringplough consolidated result operation cash flow financial condition matter discuss remainder note record liability contingency december relate expense incur year end december material opinion management base advice legal counsel ultimate outcome matter matter discuss remainder note material impact scheringplough consolidated result operation cash flow financial condition enhance matter january merck scheringplough cholesterol joint venture announce primary endpoint result enhance effect combination ezetimibe highdose simvastatin simvastatin atherosclerotic process patient heterozygous familial hypercholesterolemia clinical trial scheringplough encounter challenge result enhance trial joint venture product zetia vytorin subject media scrutiny prior fuller discussion trial result appropriate medical forum discussion schedule american college cardiology meeting march scheringplough joint venture andor joint venture partner merck inc merck receive letter congress include house committee energy commerce house subcommittee oversight investigation rank minority member senate finance table content note consolidated financial statement continue committee collectively seek combination witness interview document information variety issue relate merckscheringplough cholesterol joint venture enhance clinical trial company sale promotion vytorin sale stock company corporate officer april subpoena state official state attorney general state department justice state include connecticut new york oregon seek similar information document scheringplough cooperating investigation work merck respond inquiry addition midjanuary scheringplough aware serve litigation include civil class action lawsuit allege common law state consumer fraud claim connection scheringplough sale promotion merckscheringplough jointventure product vytorin zetia putative shareholder security class action lawsuit officer name defendant allege false misleading statement omission scheringplough representative relate timing disclosure concern enhance result allegedly violation section securities exchange act shareholder derivative action allege board director breach fiduciary obligation relate timing release enhance result letter behalf single shareholder request board director investigate allegation putative security class action warrant bring appropriate legal action behalf scheringplough scheringplough cooperate fully government investigation intends vigorously defend lawsuit file related enhance study patent matter describe patent trademark intellectual property right item business intellectual property protection critical scheringplough ability successfully commercialize product innovation potential litigation scheringploughs intellectual property right exist initiate party attempt abridge scheringplough right scheringplough protect right patent matter describe potential material effect schere plough scholl freeze away july orasure technology file action district court eastern district pennsylvania allege patent infringement scheringplough healthcare product sale scholl freeze away wart removal product matter settle material impact scheringplough financial statement stipulation dismiss action file party february awp litigation investigation scheringplough continues respond exist new litigation certain state private payor investigation department health human services department justice state industry scheringplough practice average wholesale price awp scheringplough cooperating investigation litigation investigation relate awp pharmaceutical company certain drug improperly exceed average price pay provider consequence result unlawful inflation certain reimbursement drug state program private payor base awp complaint allege violation federal state law include fraud medicaid fraud consumer protection violation claim majority case plaintiff seek class certification case class certify outcome litigation investigation include substantial damage imposition substantial fine penalty injunctive administrative remedy table content note consolidated financial statement continue security class action litigation federal security litigation follow scheringploughs announcement fda conduct inspection scheringplough manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice lawsuit file scheringplough certain name officer lawsuit allege defendant violate federal security law allegedly fail disclose material information make material misstatement specifically allege schering plough fail disclose allege risk new drug application clarinex delay result manufacturing issue allege scheringplough fail disclose allege depth severity manufacturing issue complaint consolidate action district court district new jersey consolidated amend complaint file october purport represent class shareholder purchase share scheringplough stock february complaint seek compensatory damage behalf class court certify shareholder class october notice pendency class action send member class july discovery complete motion summary judgment brief pende erisa litigation march scheringplough serve putative class action complaint file district court new jersey allege scheringplough retire chairman ceo president richard jay kogan scheringploughs employee saving plan plan administrator current director certain corporate officer messrs larosa moore breach fiduciary obligation certain participant plan complaint seek damage loss allegedly suffer plan complaint dismiss june plaintiff appeal august court appeal circuit reverse dismissal district court matter remand district court proceeding kdur antitrust litigation scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle relate generic version kdur scheringploughs longacte potassium chloride product supplement cardiac patient lederle upsher smith file abbreviate new drug application follow commencement ftc administrative proceeding allege anti competitive effect settlement resolve scheringplough favor allege class action suit file federal state court behalf direct indirect purchaser kdur scheringplough upshersmith lederle suit claim violation federal state antitrust law state statutory common law cause action suit seek unspecified damage discovery ongoing thirdparty payor action purport class action litigation file follow announcement settlement massachusetts investigation plaintiff action seek damage behalf thirdparty payor result allegation offlabel promotion improper payment physician issue massachusetts investigation tax matter october irs auditor assert interest rate swap scheringplough enter unrelated party recharacterize loan affiliate company result additional tax liability tax year september scheringplough payment irs million income tax million interest scheringplough file refund claim tax interest irs december follow irss denial scheringploughs table content note consolidated financial statement continue claim refund scheringplough file suit district court district new jersey refund tax interest refund litigation currently try newark district court scheringplough tax reserve adequate cover abovementione payment pende administrative obligation connection settlement investigation department justice attorney office eastern district pennsylvania scheringplough enter fiveyear corporate integrity agreement cia cia amend august connection settlement massachusetts investigation commence new fiveyear term failure comply obligation cia result financial penalty matter product liability beginning number complaint file jurisdiction assert claim organon usa inc organon pharmaceuticals usa inc andor organon international organon arise scheringplough marketing sale nuvare combine hormonal contraceptive vaginal ring plaintiff contend organon fail adequately warn allege increase risk venous thromboembolism vte pose nuvare andor downplay risk vte plaintiff seek damage heart attack stroke majority case currently pende united states district court district new jersey case pende wisconsin missouri new york georgia french matter base complaint french competition authority competitor france pursuant court order french competition authority obtain document french subsidiary scheringplough relate subutex product subsidiary market sell resolution matter adverse french subsidiary result imposition civil fine injunctive administrative remedy july juge des libert dtention order annulment search seizure procedural ground july french authority appeal order french supreme court april competitor request interim relief portion grant french competition authority december interim relief require scheringploughs french subsidiary publish specialized newspaper information include generic quantitative qualitative composition pharmaceutical form substitutable subutex february paris court appeal confirm decision french competition authority environmental scheringplough responsibility environmental cleanup state local federal law include comprehensive environmental response compensation liability act commonly know superfund superfund site equivalent site state law scheringplough allege potentially responsible party prp scheringplough believe remote time material liability relation site scheringplough estimate obligation cleanup cost superfund site base information obtain federal environmental protection agency epa equivalent state agency andor study prepare independent engineer probable cost pay prps scheringplough record liability environmental assessment andor cleanup probable loss incur reasonably estimate table content report independent register public accounting firm board director shareholder scheringplough corporation audit accompany consolidated balance sheet scheringplough corporation subsidiary company december relate statement consolidated operation shareholder equity cash flow year period end december audits include financial statement schedule list index item financial statement financial statement schedule responsibility company management responsibility express opinion financial statement financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position scheringplough corporation subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion financial statement schedule consider relation basic consolidated financial statement take present fairly material respect information set forth discuss note consolidated financial statement effective january company adopt statement financial accounting standard sfas revise sharebased payment discuss note consolidated financial statement effective december company adopt sfas employer account define benefit pension postretirement plan discuss note consolidated financial statement effective january company adopt financial accounting standard board interpretation accounting uncertainty income taxis audit accordance standard public company accounting oversight board united states company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting deloitte touche llp parsippany new jersey february table content scheringplough corporation subsidiary quarterly datum unaudite nth end march june september december dollar million share figure net sale cost sale gross margin sell general administrative research development acquire inprocess research development incomeexpense net special charge acquisitionrelate charge equity income cholesterol joint venture incomeloss income taxis income tax expense net incomeloss cumulative effect change accounting principle cumulative effect change accounting principle net tax net incomeloss dividend prefer share net incomeloss available common shareholder dilute earningsloss common share earningsloss available common shareholder cumulative effect change accounting principle cumulative effect change accounting principle net tax dilute earning common share basic earningsloss common share earningsloss available common shareholder cumulative effect change accounting principle cumulative effect change accounting principle net tax basic earningsloss common share dividend common share common share price high low average share outstanding diluted eps million average share outstanding basic eps million table content operating result month period end december reflect close obs acquisition november include impact purchase accounting accordance sfas business combination net sale quarter include favorable impact approximately million result reversal previously accrue rebate amount tricare retail pharmacy program federal court appeal rule pharmaceutical manufacturer obligate pay diluted earning common share month period end september calculate numerator million arithmetic sum net income available common shareholder million plus dividend million relate preferred stock dilutive denominator represent average diluted share outstanding quarter note special acquisition relate charge manufacture change consolidate financial statement additional information relate special acquisitionrelate charge charge scheringplough announce manufacturing change scheringplough approximate number holder record common share january item change disagreement accountant account financial disclosure applicable item control procedure management include chief executive officer chief financial officer evaluate scheringplough disclosure control procedure end period cover conclude scheringploughs disclosure control procedure effective conclude change scheringplough internal control financial reporting occur scheringplough recent fiscal quarter materially affect reasonably likely materially affect scheringploughs internal control financial reporting change business environment scheringplough operate scheringplough replace upgrade number information system process ongoing year connection change scheringploughs management internal control financial reporting disclosure control procedure management conclude new system effective respect control prior system management report internal control financial reporting management scheringplough corporation responsible establish maintain adequate internal control financial reporting scheringplough internal control system design provide reasonable assurance scheringplough management board director preparation fair presentation publish financial statement internal control system matter design inherent limitation system determine effective provide reasonable assurance respect financial statement preparation presentation table content scheringploughs management assess effectiveness scheringploughs internal control financial reporting december make assessment management criterion set forth committee sponsor organization treadway commission coso internal control integrate framework management assessment conclusion effectiveness internal control financial reporting december include review business process control obs management assess internal control financial reporting obs acquisition occur november year prior date consolidate financial statement allowable security exchange commission guideline obs represent approximately consolidate total asset december approximately consolidate revenue year end december base assessment management believe december scheringploughs internal control financial report effective scheringplough independent register public accounting firm deloitte touche llp issue attestation report effectiveness scheringploughs internal control financial reporting report follow table content report independent register public accounting firm board director shareholder scheringplough corporation audit internal control financial reporting scheringplough corporation subsidiary company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission describe management report internal control financial reporting management exclude assessment internal control financial reporting organon bioscience acquire november financial statement constitute total asset total revenue consolidate financial statement amount year end december accordingly audit include internal control financial reporting organon bioscience company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission table content audit accordance standard public company accounting oversight board united states consolidated financial statement financial statement schedule year end december company report date february express unqualified opinion financial statement financial statement schedule include explanatory paragraph company adoption statement financial accounting standard sfas revise sharebased payment sfas employer account define benefit pension postretirement plan financial accounting standard board interpretation accounting uncertainty income taxis deloitte touche llp parsippany new jersey february table content iii item director executive officer registrant information concern director nominee director incorporate reference proposal elect thirteen director oneyear term scheringplough proxy statement annual meeting shareholder information concern executive officer include file caption executive officer registrant information concern compliance section exchange act incorporate reference section beneficial ownership report compliance scheringplough proxy statement annual meeting shareholder information concern audit committee audit committee financial expert incorporate reference information audit committee board director practice audit committee report scheringplough proxy statement annual meeting shareholder scheringplough adopt code business conduct ethic standard global business practice applicable employee include chief executive officer chief financial officer controller scheringploughs standard global business practice available investor relation section scheringplough website wwwscheringploughcom addition write copy material provide charge write office corporate secretary scheringplough corporation gallop hill road mail stop kenilworth new jersey scheringplough intend satisfy disclosure requirement item form amendment waiver provision standard global business practice post information website address specify item executive compensation information concern executive compensation incorporate reference executive compensation scheringplough proxy statement annual meeting shareholder item security ownership certain beneficial owner management relate stockholder matter information concern security ownership certain beneficial owner management incorporate reference stock ownership scheringplough proxy statement annual meeting shareholder table content equity compensation plan information follow information relate plan equity security scheringplough issue employee director scheringplough plan equity security issue nonemployee stock incentive plan certain stock option transferable family member employeeoptionee relate trust column column number security number security issue column remain available exercise weightedaverage future issuance outstanding exercise price equity compensation option warrant outstanding option plan exclude security plan category right warrant right reflect column equity compensation plan approve security holder stock incentive plan stock incentive plan stock incentive plan stock incentive plan director compensation plan equity compensation plan approve security holder scheringplough ireland approve profit sharing scheme organon ireland limited employee share participation scheme intervet ireland limited employee share participation scheme total plan permit eligible employee work certain scheringplough irish subsidiary enjoy tax advantage annual bonus vary percent percent pay pass trustee trustee purchase share common stock open market allocate share employee account euro defer year employee employee sell withdraw share allocate account year item certain relationship relate transaction information concern certain relationship relate transaction incorporate reference certain transaction procedure relate party transaction director independence assessment scheringplough proxy statement annual meeting shareholder information concern director independence incorporate reference director independence scheringploughs proxy statement annual meeting shareholder item principal accountant fee service information concern principal accountant fee service incorporate reference proposal ratify designation deloitte touche llp audit scheringplough books account scheringplough proxy statement annual meeting shareholder table content item exhibit financial statement schedule follow document file report financial statement financial statement set forth item financial statement schedule table content merckscheringplough cholesterol partnership combine financial statement index age combine statement net sale contractual expense year end december combine balance sheet december combine statement cash flow year end december combine statement partner capital year end december note combine financial statement year end december independent auditor report schedule valuation qualifying account schedule list omit applicable require table content index exhibit indicate exhibit commission file number exhibit number description location amend restate certificate incorporation incorporate reference exhibit scheringplough file september amend restate bylaw incorporate reference exhibit scheringplough file june right agreement scheringplough incorporate reference exhibit bank new york date june scheringploughs file june form participation right agreement incorporate reference exhibit scheringplough chase manhattan bank scheringploughs registration statement form national association trustee amendment file december file indenture date november incorporate reference exhibit scheringplough bank new york trustee scheringplough file november cii supplemental indenture include form note incorporate reference exhibit date november scheringploughs file november ciii second supplemental indenture include form note incorporate reference exhibit date november scheringploughs file november civ global senior note incorporate reference exhibit civ scheringploughs year end december global senior note incorporate reference exhibit scheringploughs year end december cvi supplemental indenture include form note incorporate reference exhibit date september scheringploughs file september cvii fourth supplemental indenture include form note incorporate reference exhibit date october scheringploughs file october directors compensation plan amend restate incorporate reference exhibit hiii effective june amendment scheringplough period end september september stock incentive plan incorporate reference exhibit scheringplough period end september bii amendment stock incentive plan effective incorporate reference exhibit february scheringploughs period end march biii amendment stock incentive plan effective incorporate reference exhibit february scheringploughs year end december stock incentive plan amend february incorporate reference exhibit scheringplough year end december table content exhibit number description location stock incentive plan amend restate attached effective february letter agreement date november incorporate reference exhibit eiii robert bertolini scheringplough scheringploughs year end december eii employment agreement effective change incorporate reference exhibit control date december robert scheringploughs file december bertolini scheringplough corporation eiii employment agreement date incorporate reference exhibit carrie cox scheringplough scheringploughs file eiv employment agreement date april incorporate reference exhibit fred hassan scheringplough scheringploughs file april employment agreement date december incorporate reference exhibit thomas koestler phd scheringploughs year end december scheringplough evi letter agreement date march incorporate reference exhibit thomas sabatino scheringplough scheringploughs period end march evii employment agreement effective change incorporate reference exhibit control date april thomas scheringploughs year end december sabatino scheringplough eviii employment agreement date december attach brent saunder scheringplough eix form employment agreement effective change incorporate reference exhibit control scheringplough certain scheringplough year end december executive new agreement begin december operation management team incentive plan incorporate reference exhibit mii amend restate effective june scheringploughs period end september cash longterm incentive plan amend incorporate reference exhibit restate effective january scheringplough year end december longterm performance share unit incentive plan incorporate reference exhibit amend restate effective january scheringplough year end december transformational performance contingent share incorporate reference exhibit program scheringplough year end december severance benefit plan amend restate attached effective january saving advantage plan amend restate incorporate reference exhibit exiii effective january scheringploughs period end september table content exhibit number description location supplemental executive retirement plan amend incorporate reference exhibit restate january scheringploughs year end december retirement benefit equalization plan amend incorporate reference exhibit restate january scheringploughs year end december executive incentive plan amend restate incorporate reference exhibit october scheringploughs year end december defer compensation plan amend restate incorporate reference exhibit october scheringploughs year end december amend restate define contribution trust incorporate reference exhibit aii scheringploughs year end december amend restate serp rabbi trust agreement incorporate reference exhibit scheringploughs year end december cholesterol governance agreement date incorporate reference exhibit scheringplough merck inc scheringploughs date october party signatory thereto amendment cholesterol governance incorporate reference exhibit agreement date december scheringploughs file october scheringplough merck inc party signatory thereto master agreement date december incorporate reference exhibit scheringplough merck inc scheringploughs file october party signatory thereto letter agreement date april relate consent incorporate reference exhibit decree scheringplough period end march distribution agreement scheringplough incorporate reference exhibit schering centocor inc date april plough amend year end december file amendment agreement distribution agreement incorporate reference exhibit centocor inc development llc scheringploughs file december scheringplough ireland company share purchase agreement akzo nobel incorporate reference exhibit scheringplough international scheringplough scheringploughs file october corporation computation ratio earning fix charge attach standard global business practice cover incorporate reference exhibit employee include senior financial officer scheringplough file september subsidiary registrant attach table content xhib number description location consent independent register public accounting attach firm independent auditor consent attach power attorney attach sarbanesoxley act section certification attach chairman board chief executive officer sarbanesoxley act section certification attach executive vice president chief financial officer sarbanesoxley act section certification attach chairman board chief executive officer sarbanesoxley act section certification attach executive vice president chief financial officer compensatory plan contract arrangement certain portion exhibit omit pursuant request confidential treatment nonpublic information file separately security exchange commission pursuant rule securities exchange act amend copy